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1.0 INTRODUCTION  
 
1.1 Abstract   
Since its introduction in 2006, the human papilloma virus (HPV) vaccine has made 
substantial developments. The use of the vaccine was expanded to include males. The 
completion dose series was decreased from three to two shots, if started before the age of 
15. The cost of the vaccine is fully covered by private insurance and public programs for 
various ages ranging from 9 to 26 years old1. With these improvements the HPV vaccine 
has the capability to safely and significantly prevent and reduce many cancers that cause 
the deaths of women and men across the United 1,2. Therefore, the underuse of the HPV 
vaccine is a serious but correctable threat to progress against cancer3,4. During 2012-
2016, an estimated average of 34,800 HPV-attributable cancers were diagnosed each 
year. Among these estimated cancers, 92%  were attributable to the HPV types that are 
included in the 9-valent HPV vaccine and could have been prevented if HPV vaccine 
recommendations were followed5. However, HPV vaccination rates across the U.S. 
remain low6.  
Using public health data sources, choropleth maps, new variables of Health Department 
(HD) clinic access and prediction modeling, this research advanced the field of health 
services research by informing the third goal of the President’s Cancer Panel 2012-2013 
report: maximize access to HPV vaccination3. The short-term impact of this research 
quantified and located HPV vaccination for adolescents, in addition to highlighting 
prognostic indicators of access and identifying barriers to HPV vaccination uptake among 
HD clinics at the county level in Georgia. The long-term impact of this research provided 
greater insight for targeting efforts to optimize HPV vaccine uptake at the county level in 
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South Carolina and in other states with low HPV vaccination coverage. This research 
demonstrated the important use of small area estimation by public health professionals in 
states with low HPV vaccination coverage and limited or no immunization registry data 
for small geographic areas.  This research provided valuable data toward the access of 
vaccination services and the dissemination and implementation of HPV vaccination 
interventions at the county level. Ultimately the findings from this study may be used to 
predict correlations to the incidence of HPV-associated cancers, which may help reduce 
public health costs, morbidity and mortality related to HPV infections in the United 
States.   
1.2 Specific Aims 
The underusage of the human papilloma virus (HPV) vaccine is a serious but 
correctable threat to the prevention of cancer4. More than 90% of cervical and anal 
cancers, approximately 70% of vaginal and vulvar cancers, 60% of penile cancers, and 
about 70% of oropharyngeal cancers are a result of a HPV infection7. As of 2019, 54.2% 
of U.S. adolescents are fully vaccinated with the HPV vaccine, and 71.5% of them have 
received at least one dose of the HPV vaccine average6. National efforts to increase HPV 
vaccination to 80% are being made8 and include resources often administered and utilized 
at the county level through the state health department (HD). However, the lack of county 
level HPV vaccination coverage data in many states is a major obstacle to effectively 
monitor health department resource utilization. Efficiently allocating health department 
resources is necessary to improve HPV vaccination coverage and ultimately protect 
adolescent residents from HPV-attributable cancers9,10.  
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The overarching goal of this research is to generate a predictive model of county 
level HPV vaccination coverage rates in SC and Georgia (GA) to address access barriers 
to HPV vaccine uptake. Because the tetanus, diphtheria and pertussis (Tdap) vaccine is a 
school mandated vaccine for all adolescents in both states and an indicator of access to 
vaccination services, we evaluated adolescents who received the HPV vaccine among 
those who have received the Tdap vaccine.  Using factors associated with HPV 
vaccination we will evaluate additional indicators of access to health department (HD) 
clinics: the number of public and private clinics, the number of HD clinics with Vaccine 
For Children (VFC) provider registration, and availability of public transportation. We 
used the number of administered HPV and Tdap vaccine doses previously collected from 
each state’s immunization registry for the years 2016-2018. Given that SC and GA are in 
the same Region 4 of the Department of Health and Human Services (HHS) and their 
population demographics are similar, it is expected that vaccination rates in SC’s counties 
would be comparable to GA’s counties. However, GA’s adolescent HPV vaccination 
coverage trend of greater than or equal to one dose exceeds or is close to the national 
average. When population subgroups share characteristics, the systematic underuse of 
vaccination services may indicate a problem with the equity of access11. Eliciting a 
secondary data analysis of the vaccination data from both states, we evaluated our 
primary hypothesis that HPV coverage rates are associated with the equity of access to 





1.2.1 Aim 1  
Specific Aim 1: Characterize all counties in GA based on administered doses 
of the HPV vaccine, the Tdap vaccine and HD clinic access. Graphical maps were 
created for each state using Bayesian spatial analysis of HPV and Tdap vaccine doses, 
public transportation routes and VFC provider registration by public and private health 
clinics. Hypothesis 1.1: In GA, administered doses of the HPV vaccine and the Tdap 
vaccine will be associated with indicators of HD clinic access.   
1.2.2 Aim 2 
Specific Aim 2: Develop and validate a predictive model to describe the 
association between county level HPV vaccination coverage and HD clinic access in 
GA among Tdap vaccinated adolescents. Controlling for known factors associated with 
HPV vaccination, we used 2016 and 2017 data from GA to predict 2018 HPV 
vaccination coverage rates. Hypothesis 2.1: Significant factors of HPV vaccination 
coverage will be predicted at the county level in GA among Tdap vaccinated adolescents. 
1.2.3 Aim 3 
Specific Aim 3: Apply the predictive model of HPV vaccination coverage 
developed from GA data to SC. Using the final model selected in Aim 2, the best set of 
beta estimates were applied to all counties in SC via linear regression to predict HPV 
vaccination coverage. Hypothesis 3.1: Differences in SC’s HPV vaccination coverage 







This dissertation research builds upon and extends my mentor’s current research of a 
statewide HPV vaccination awareness campaign in South Carolina to increase HPV 
vaccination rates. Using the adolescent population (ages 13-17) of South Carolina, two 
primary research questions are examined: 1) who is getting vaccinated and 2) what can be 
done to improve HPV vaccination. These research questions prompted the consideration 
of a better tool for HPV vaccination surveillance.  
2.2 Introduction 
In 2016, South Carolina had the lowest rate of HPV vaccine completion among 
adolescent girls in the United States (30.8%) and second-to-last for up-to-date (UTD) 
vaccination among adolescent boys (27.4%). In 2017, 38% of males and 47.4% of 
females were up-to-date12. As a result, South Carolina had the third largest increase in 
HPV vaccinations in the United States from 2016 to 2017. Currently, South Carolina is 
close to the national average of 54.2%6 but the Healthy People 2030 goal is to reach 
80%8. Problems with access to care as they relate to HPV vaccination in South Carolina 
consist of barriers at different levels within the patient, provider, health system and 
political environment. Patient barriers include: lack of provider recommendation, lack of 
knowledge about the vaccine and HPV related diseases, concerns about vaccinating an 
adolescent against a sexually transmitted infection, the disbelief that the vaccine is 
essential, particularly with males, and concerns about the vaccine’s safety and cost. 
Provider barriers include: a lack of understanding about HPV-related diseases, 
specifically for males, safety concerns about the vaccine, concerns about reimbursement 
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for vaccines, personal attitudes, being uncomfortable with talking to parents and children 
about a topic related to sexual behavior, concerns about parental resistance, preferring to 
vaccinate older rather than younger adolescents, lack of vaccine reminder and recall 
systems, and limited time to provide education about the vaccine. Health system and 
political barriers include: the lack of electronic health record reminders13,  a lack of 
vaccine insurance coverage among some populations and a lack of legislation for 
mandatory vaccination 14.   
However, South Carolina is just a small piece of the big picture, as national and 
state levels HPV vaccination coverage rates still vary by geography and race. Reported 
disparities by geographic location broadly reference metropolitan vs non-metropolitan 
areas. HPV vaccination rates are particularly low in rural areas even though the uptake of 
other adolescent vaccines is comparatively higher. In urban areas over 50% of the 
adolescents are up to date on their HPV vaccination compared to 42% of adolescents in 
rural areas15. Racial disparities have been reported among Black, Hispanic and Asian 
adolescents being more likely to initiate the HPV vaccine series compared to White 
adolescents, but less likely to complete the vaccine series16. Previous studies have also 
identified factors at the local level associated with HPV vaccination coverage are the 
uptake of other adolescent vaccines, gender, race/ethnicity, socioeconomic status, 
religiosity, political ideology, education policies and insurance status17–19. Religiosity and 
political ideology have been used as proxy measures for macro-level acceptability and 
attitude towards the HPV vaccine19. Differences in HPV vaccination uptake also exist 
between certain geographically distinct populations and among adolescents who have 
received the school mandated tetanus, diphtheria and pertussis (Tdap) vaccine. While 
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mandates have been effective with other vaccines, states with HPV vaccine mandates 
have similar rates of HPV vaccination compared to those without mandates, thus 
indicating that differences are not fully understood 18,20. While there is a need to further 
explore these disparities, within state variability of HPV vaccination is either unknown or 
rarely reported21 and in some states county level HPV vaccination coverage rates are 
currently not available.  
 In terms of barriers, a distinct contributing factor to incomplete HPV vaccination 
among adolescents is parental hesitancy. Parental hesitancy contributes to missed 
opportunities22, physician hesitancy 3, and the physicians’ perception of parental 
reservations 23. In 2014 a qualitative study was published that investigated the rationale of 
parents/guardians and providers for delaying or administering the HPV vaccination to 
girls. Among providers who reported that over 80% of their patients receive HPV 
vaccination, the higher uptake was driven by always recommending co-administration of 
HPV, tetanus, and meningococcal vaccines and emphasizing cancer prevention22. Many 
of the missed opportunities for HPV vaccination were due to parents and providers 
agreeing to delay vaccination until the risk for sexual activity was predicted22. Other 
studies have reported that health care providers also perceived parental attitudes and 
hesitancy related to vaccinating an adolescent against a sexually transmitted infection as a 
barrier. Lack of provider recommendation, in turn, is one of the most influential reasons 
why parents do not get their adolescents vaccinated against HPV. Additional key 
contributors of parental hesitancy are needing more information about the HPV vaccine, 
the belief that their child is too young for the vaccination, safety of the vaccine, cost of 
the vaccine, and finding a clinic that offers the HPV vaccine 23.  
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To address parental hesitancy effective HPV vaccine messaging in an important 
strategy to increase HPV vaccine uptake. In South Carolina, the most trusted messengers 
include healthcare organizations, and providers, patient and parent peers, and local public 
figures24–26. Messages that appeal to parents’ moral responsibility to protect children 
against cancer are recommended due to moral values such as purity and liberty being 
associated with vaccine hesitancy. Additionally, messages that highlight HPV’s 
connection to sexual activity negatively influenced vaccine-hesitant parents, specifically 
in South Carolina due to a large population that identifies as Christian. Therefore, 
disseminating messages from the CDC that highlight cancer prevention, knowledge about 
HPV transmission, risks and prevention are recommended. Examples of messages are 
“The HPV vaccine is safe, effective and provides long-lasting protection”, “HPV Vaccine 
is Cancer Prevention” and “One vaccine plus two doses equals protection against six 
types of cancer”. Overall, HPV-specific messages that align with constructs from 
behavior models such as the Health Belief Model and Social Cognitive Theory to 
communicate the high risk for HPV infection, the severity of cancers associated with 
HPV, a cue to action for parents to protect children from known risk and the 
normalization of HPV vaccination as standard practice are effective 26. Recommended 
strategies for disseminating these messages are using personal stories from cancer 
survivors and parents who have vaccinated their children. Additionally the use of trusted 
experts to discuss scientific data emphasizing the safety and efficacy of the HPV vaccine 
across multiple media platforms will engage a wider audience and effectively 




2.3 Molecular Biology of HPV that Drives Carcinogenesis 
Papillomaviruses are a distinct taxonomic family, the Papillomavirida. The bovine 
papillomavirus type 1 (BPV-1) and human papillomavirus type 1a (HPV-a1) genomes 
were the first papillomavirus genomes to be completely sequenced. Interestingly, the 
BPV-1 has been utilized as a prototype for studies of the molecular biology of 
papillomaviruses. Papillomaviruses replicate and assemble entirely in the nucleus of a 
cells. The expected replication cycle has an early and a late phase. The early phase 
includes viral entry, and the initial viral genome replication, stimulation of cell division 
and inhibition of apoptosis in the infected cell. The late phase includes viral genome 
amplification, virion formation and its release into the surrounding environment from the 
surface of the epithelium. Specifically during the early phase the virus infects the 
keratinocytes (basal cells) in the basal epithelial layers 27,28. Once infected, basal 
epithelial cells divide, the viral genome copies are replicated and separated equally into 
daughter cells. An infected daughter cell will make multiple copies and move up through 
the various epithelial layers. During this process there is a pattern of viral gene 
expression in response to epithelial differentiation that is specifically connected to 
different epithelial layers 27.  
The viral genome responds by expressing viral regulatory proteins: E1, E2, E4, 
E5, E6 and E7 from the early region of the viral genome and two structural viral capsid 
proteins: L1 and L2 from the late region of the genome28. E1 and E2 support viral DNA 
replication and the regulation of transcription so that the infected basal cells can be 
maintained for a long period. E4 is linked with reassembling differentiated basal cells for 
the release of progeny viral particles and regulation of the cell cycle. E5, E6 and E7 are 
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viral oncogenes and their expression initiates cell immortalization and transformation by 
coordinating a host cell environment suitable for viral DNA replication which promotes 
host cellular DNA synthesis and prevents apoptosis. E5 is involved in keratinocyte 
signaling and immune evasion. E6 and E7 inactivate interferon (IFN) regulatory factor 
(IRF) so that the viruses can remain as persistent, asymptomatic infections in 
differentiating epithelial cells where cell division would normally be repressed. L1 and 
L2 are expressed in cells replicating viral DNA in the upper epithelial cells. Taxonomic 
status of papillomavirus types, subtypes, and variants is based on the sequence of their L1 
genes which differ from each other by at least between 2 – 10% 27–29.  
Papillomavirus infections typically result in benign lesion however, the human 
papillomavirus (HPV) infection sometimes develops cancerous lesions. HPV is a small 
non-enveloped deoxyribonucleic acid (DNA) virus that infects skin or mucosal cells. The 
circular, double-stranded viral genome of about 8 kilobases in length. As a member of 
Papillomavirida, the HPV genome encodes for 6 early proteins responsible for virus 
replication and 2 late proteins that are the viral structural proteins. The cancerous lesions 
emerge once HPV infects a cell and produces oncoproteins E6 and E7 that are 
particularly instrumental in the conversion of normal cells to cancerous ones. These 
inappropriately dividing cells in the upper epithelial layers would normally be disposed 
via apoptosis but E6 promotes tumor cell growth by breaking down the tumor suppressor 
protein p53 and inactivating pro-apoptotic proteins such as Bak or Bax. E6 degrades p53 
thorough the ubiquitin pathway by targeting it for proteasome mediated degradation 
which allows HPV infected cells to survive and support replication 27,30. Normally, the 
tumor suppressor protein p53 prevents the transition of cells from the checkpoint G1 
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phase to the replication S phase, thus allowing for the repair of damaged DNA or the 
initiation of apoptosis.  
For that reason it has been suggested that high risk HPV types do not have a 
functional G1 checkpoint and that the E6 protein has been shown to influence the 
telomerase enzyme to elongate chromosomal telomeres which is necessary for cell 
immortalization 31. As a result, the ability to target p53 for degradation contributes to the 
impact of oncogenic activity. With high risk HPV type E6 proteins, the interaction of an 
E6-associated protein (E6-AP) is necessary for the complex formation of E6 with p53. 
Furthermore, the E6-AP can initiate the ubiquitination of cellular components without 
E6, so the function of E6-AP is not just to mediate the binding of E6 to p53, but it 
provides the functional link to the ubiquitin system as an E3 ubiquitin ligase. However, 
this complex formation is not definitively seen with low risk HPV type E6 proteins 32. 
The weak interaction between low risk HPV type E6 proteins may explain their inability 
to target p53 for degradation, resulting in a lack of oncogenic activity. However, it is also 
possible that additional proteins are required to facilitate the interaction of E6-AP with 
low risk HPV type E6 proteins and/or that the E6-AP complexes are not detectable under 
current conditions of coprecipitation experiments 33. The E6 protein further cooperates 
with the E7 protein to convert normal cells to cancerous one. E7 binds to the 
retinoblastoma protein (pRb) in the pocket domain. The pocket domain sequences are 
necessary for its tumor suppressor function which negatively regulates the cell cycle in 
the G1/S and G2/M transitions.  
In a normal cell, pRb and E2F- family transcription factors regulate cell 
replication together by keeping the cell ‘off’ in the resting phase, G0, before the cell goes 
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into mitosis and divides. Therefore when E7 blocks the interaction between pRb and 
E2F-family transcription factors, it activates the E2F factors to stimulate replication and 
cell division 27,30. Specifically, when bound to pRB, E7 promotes C-terminal cleavage of 
pRB by the calcium activated cysteine protease calpain which is required for the 
proteasomal degradation of pRb. Additionally, E7 may initiate cancerous cell 
transformation by binding the AP1 transcription factors to prevent the differentiation of 
keratinocytes and by interfering with other cell cycle regulators such as cyclin A and 
cyclin-dependent kinase2 29,31. However, E7 proteins from low risk HPV types inactivate 
cellular pRB tumor suppressor proteins less efficiently than high risk HPV types 28 and 
the genetic variation of E7 within an HPV type in specific regions of the viral genome 
has been suggested to impact carcinogenicity. Specifically, in a recent study with cervical 
cancer it was shown that the conservation of the 98 amino acids of E7 is critical for HPV 
16 carcinogenesis. Even compared to E6, E7 has significantly fewer, rare non-silent 
genetic variants in cancers and E7 was shown to be less constrained in benign infections. 
These results were consistent in different geographic locations and racial groups and thus 
suggests that E7 genetic variation notably decreases the risk of invasive cancer 34. 
HPV is the most common sexually transmitted infection in the United States but 
only approximately 10% to 15% of infected persons have persistent infections, of which a 
small portion has the potential to progress to invasive cancer 35. This suggests that host 
defense mechanisms are successful at clearing the initial HPV infection for the majority 
of HPV infected persons. Host defense mechanisms against HPV are physical barriers, 
innate immunity and adaptive immunity. Physical barriers of basal keratinocytes, the host 
cells of HPV, are the skin and mucous membranes secrete a thick protective fluid and 
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antimicrobial peptides. HPV moves across the skin and mucous membrane via tissue 
damage and once inside many of its particles are degraded via host autophagy. The 
nuclear envelope also blocks HPV DNA from entering the nucleus. Innate immunity uses 
pathogen sensors to recognize HPV DNA once HPV enters a host cell. The high 
expression of nucleic acid-sensing toll-like receptors (TLR) is significantly correlated to 
women clearing the initial HPV infection. The HPV infected microenvironment also 
attracts dendritic cells, Langerhans cells, natural killer cells and natural killer T cells, thus 
suggesting that the early inflammatory response may be critical for initiating a strong 
defense against HPV infection. Adaptive immunity is seemingly less instrumental 
because the HPV lifecycle is only intraepithelial, and virions are only produced from the 
fully differentiated upper layer of skin. In the outer layers of epithelium, viral DNA is in 
capsids and progeny virions are released to re-initiate infection. Therefore, there are no 
virus induced cell eruptions or released viruses in the blood. However, host T cell 
responses are required to eliminate HPV infected cells. To escape being detected by the 
immune system HPV alters host gene expression, dysregulates protein functions, hides 
surface expression of MHC-I molecules to evade immune defenses and establish 
persistence. As a result, the continued presence of the viral genome over a period of 
several years in actively dividing epithelial cells results in a persistent infection 27,29,35.  
2.4 Etiology of HPV Vaccine Development  
While 90% of HPV infections do not show symptoms and clear naturally within 
two years, persistent infections can cause cancer and genital warts. There are more than 
100 types of HPV. More than 40 HPV types can infect the genital areas of men and 
women, including the skin of the penis, vulva, and anus, as well as the linings of the 
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vagina, cervix, and rectum. These types can also infect the lining of the mouth and throat. 
Of these, 13 HPV types (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59 and 66) can cause 
cervical cancer, and one of these types can cause cancers of the vulva, vagina, penis, 
anus, and certain head and neck cancers; specifically, the oropharynx, which includes the 
back of the throat, base of the tongue and tonsils 36. As a result, more than 90% of 
cervical and anal cancers, approximately 70% of vaginal, vulvar and oropharyngeal 
cancers, and 60% of penile cancers are the result of a HPV infection 7. In particular, HPV 
types 16 and 18 are associated with about 70% of cervical cancers, with type 16 having 
the strongest evidence for overall carcinogenicity and types 6 and 11 are associated with 
90% of genital warts 37.  
Gardasil 9, the only HPV vaccine available for use in the United States, prevents 
infection from these four types (16,18,6,11) and five additional cancer-causing types 
(31,33,45,52 and 58). Therefore, of the total identified 13 HPV types there are five 
remaining HPV types (35,39,51,56,59 and 66) associated with cervical cancer that need 
vaccine development 38. There are numerous other individual reports of human 
papillomavirus types in cancers of the esophagus, prostate, bladder, breast, lung and other 
organ sites. With the exception of nail bed cancers, none of these reports show a 
consistent association of the virus with the respective site. Therefore, although high risk 
HPV types may sometimes cause cancers in atypical locations, the inconsistency of these 
reports does not provide strong support for researching these additional locations39.  
Many of the ongoing searches for novel HPV types use established consensus 
primers in polymerase chain reactions. This somewhat allows for the detection of 
partially homologous sequences because in theory HPV types not discovered by these 
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primers or those very distantly related to a known type of this virus group, would likely 
escape detection 39. The direct detection of HPV genomes and their transcripts could be 
improved through hybrid testing procedures. However, new technical approaches that 
might increase the sensitivity of detecting new HPV types need to consider the clinical 
significance because not all HPV infections are persistent and lead to a clinically relevant 
disease. The development of a new technical approach that determines if the presence of 
multiple infections is a useful marker for persistent infection and the onset or progression 
of disease would assist with clinical significance.  
Current approaches to increase the clinical sensitivity are testing only for 
clinically relevant high risk HPV types, adding a viral load measure and testing for high 
risk HPV E6 and E7 transcripts 38. In spite of current technical limitations, a defining 
characteristic of cancer associated with persistent infection by the high risk HPV types is 
that viral genomes are commonly found integrated into the cancer cell genome, however, 
minute viral variations may show risk differences that could distinguish molecular 
mechanisms. It is already well established that while all the high-risk HPV types are 
genetically related, they greatly differ in prevalence, evolutionary fitness and in risk of 
causing precancer and cancer. HPV genetic variation represents slow evolutionary drift 
and the HPV types are made up of phylogenetic variant lineage as well as sublineage 
evolutionary clades that differ from each other by approximately 1% to 9% 28,34. These 
minute viral variations may contribute to the increased number of identified HPV strains 
and the corresponding number of carcinogenic strains.  
Understanding the unique carcinogenicity of high-risk HPV types, such as 
identifying patterns to explain the amino acid changes in HPV proteins, would be useful 
19 
 
for vaccine development. The use of antibodies to inhibit protein function is a viable 
option for treatment because viruses express proteins that are different from those 
expressed by the cell and they are directly involved in causing disease. However, the 
disease associated proteins resemble their normal cellular counterparts at most of the 
sites, making the discovery of molecules that can specifically target disease associated 
forms difficult. Specifically, one reason for the difficulty in targeting HPV infection is 
because most papillomavirus proteins bind to cellular proteins instead of using their own 
enzymatic activity to enact their effects. Alternatively, since E6 and E7 are co-expressed 
in cancers from a bicistronic mRNA, RNA interference could be a promising approach 
for vaccine development as well 29,40. Being immune to one HPV type may not prevent 
the infection of another HPV type. Therefore, the ultimate prevention goal would be to 
have a prophylactic vaccine that includes all carcinogenic HPV strains according to 
potential genetic variation of HPV types and targets HPV proteins E6 and E7.  
2.5 The Efficacy and Delivery of HPV Vaccination 
Pressing questions related to HPV vaccination efficacy and delivery are who 
should get the vaccine, is it safe, and is it effective. According to CDC the best age for 
boys and girls to get the Gardasil vaccine is 11 to 12 years of age since children are not 
yet sexually active at this age. Data suggests that 6% of US high school students had 
sexual encounter before age 13. Also, research has suggested that girls who get 
vaccinations at age 12-16 have significantly more antibody titers present in their blood 
compared to older women favoring that the vaccinations be administered at an early age. 
As more antibody research is done with boys, the central idea is to get people protected 
against the virus before they encounter the virus for the first time. The vaccine can also 
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be given as early as 9 years of age and is now approved by the U.S. Food and Drug 
Administration (FDA) for men and women up to 45 years of age. Children who start the 
series between 9 and 14 years of age should get two shots of the HPV vaccine six months 
apart. Adolescents who start the series after their 15th birthday will require three doses of 
the HPV vaccine, with the second dose 2 months after the first, and the third dose 6 
months after the first. This same three dose schedule is recommended for adults and for 
immunocompromised individuals 41,42.   
Twelve years of monitoring and research have shown that the HPV vaccine is safe 
and effective in large clinical trials and extensive post-licensure data further supports the 
vaccine’s safety and efficacy. All of the HPV vaccines use virus like particles which 
mimic the viral capsid but do not contain genetic material and are produced in biologic 
systems, which have well established safety records. In the large licensing trials, baseline 
HPV infection status was measured through serologic testing and DNA detection in 
cervical specimens. Efficacy in the overall trial populations was consistently lower than 
among those without baseline HPV infection. This revealed that many trial participants 
were already sexually active and previously infected with vaccine HPV types; thus 
emphasizing the importance of receiving vaccination before the onset of sexual activity to 
maximize effectiveness 43. Since cancer registries do not routinely collect data on 
whether HPV is in the cancer tissue, case-control studies are emphasized as opposed to 
prospective cohort studies due to a larger number of invasive cancers that have been 




Currently, there is no scientific evidence to associate the HPV vaccine with any 
specific adverse event43–47. However, like any vaccine or medicine, HPV vaccines can 
cause side effects. The most common side effects are pain, redness, or swelling in the arm 
where the shot was given; dizziness, fainting, nausea, and headache 48. It was reported 
that recipients of the 9-valent vaccine were slightly more likely to experience these side 
effects than recipients of the quadrivalent vaccine (90.7% vs 84.9%) possibly due to 
higher amounts of virus like particles and adjuvants in the 9-valent vaccine 10. In an 
analysis of seven trials in which over 15,000 individuals received at least one dose of the 
9-valent vaccine, serious adverse events occurred in less than 0.1%43. Some surveys of 
parents of adolescent girls identified a concern the HPV vaccine to have a behavior 
impact on sexual promiscuity. However, studies have not confirmed an association 
between vaccination and increased sexual behavior 43. Additionally, multiple large 
studies have provided evidence that the HPV vaccine is as safe as any other vaccination 
and that those who receive this vaccine are not at a higher risk of any negative events 
when compared to receiving any other vaccine immediately or in the long-term future49. 
Therefore the cancer prevention benefits of HPV vaccination far outweigh the potential 
risk of side effects 48. 
Research shows that HPV vaccine protection is long-lasting. Current studies have 
followed vaccinated individuals for 12 years and show that there is no evidence of 
weakened protection over time. HPV vaccination research includes over 10 years of data 
and continues to be monitored by the Centers for Disease Control and Prevention (CDC) 
and the Food and Drug Administration (FDA)48. HPV vaccination has shown high quality 
duration of protection for this 10 year time period even though the precise level of 
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antibody needed for protection against infection is unknown 43. As a result, over 120 
million doses of the HPV vaccine have been administered in the United States.  
A potential clinical trial to further address HPV vaccine delivery would be one that 
finds a biomarker related to immune response and host susceptibility to HPV. Focusing 
on cervical cancer would provide an adequate source population because nearly all cases 
of cervical cancer types are resultant of an HPV infection and the primary prevention 
strategy against cervical cancer is HPV vaccination.  Hispanic women have the highest 
incidence rate of cervical cancer, however, the highest death rate from cervical cancer is 
among African American women. In comparison to White women, African American 
women are more likely to be diagnosed with cervical cancer. Of the known HPV strains 
that are strongly associated with cervical cancer, it is unclear if these various strains are 
significant to mortality. Research studies have indicated that biologic, socioeconomic, 
cultural, environmental and other factors may affect cervical cancer incidence and 
mortality 50. Therefore, the investigation of disparities in immunologic host susceptibility 
factors due to ethnicity are of interest. The independent variable of interest would be the 
clearance of high-risk HPV infection types by African American women and the 
dependent variable of interest would be the mortality of African American women with 
cervical cancer. The relationship between the clearance of high-risk HPV type infections 
by African American women and the mortality of African American women with cervical 
cancer, is potentially due to how the immune system responds to viral infections. Quach 
et al investigated the differences in the transcriptional responses of Africans and 
Europeans to immune stimulation. They found distinct differences among antiviral and 
inflammation-related genes that significantly differed in responsiveness between Africans 
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and Europeans. Specifically, the master regulator, TLR1, controls the inflammatory 
response in Europeans and contributes significantly to differences in the strength of the 
inflammatory response between Africans and Europeans 51. This evidence provides good 
support for genetic variants of immune responses. However, there does not seem to be 
any exploration as to the TLR pathways that are activated and regulated in Africans for 
their inflammatory responses. Also, the variants affecting immune responses in African 
genomes are not discussed. Therefore, this evidence appears to be lacking sufficient 
information on African genetic differences and regulatory variants to adequately 
determine differences in host immune responsiveness between Africans and Europeans.  
Banister et al (2015) investigated the persistence of high-risk HPV genotypes 
between African American and European Women of College Age. They found that of the 
2,121 clinic visits for the study, on 40% of them European American women were HPV 
positive and on 51% of them African American women were HPV positive. For 
European American women, 37.1% of the visits produced high risk HPV types and 8.7% 
produced low risk HPV types. For African American women, 47.4% of the visits 
produced high risk HPV types and 14.4% produced low risk HPV types. Using 
multivariable analysis of the association between ethnicity and high-risk HPV infection, 
African American ethnicity and lifetime number of sex partners was significant; thus, 
indicating that clearance of high-risk HPV could be different between African American 
and European American women. The required time for 50% of high-risk HPV infections 
to clear was almost double the days for African American women compared to European 
American women. African American women also had 1.61 times the odds of not clearing 
a high-risk HPV infection compared to European American women. African American 
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women had more abnormal Pap test results (ASCUS, LSIL, and HSIL) compared to 
European American women and were significantly associated with an abnormal Pap test 
result when the lifetime number of sex partners, HPV vaccine receipt and smoking were 
controlled for. However, high risk HPV type was significantly associated with an 
abnormal Pap test result when ethnicity, the lifetime number of sex partners, HPV 
vaccine receipt, and smoking were controlled for. This suggests that the high-risk HPV 
status is the reason for differences in abnormal Pap test results between African 
American and European American women. Therefore, the increased risk of an abnormal 
Pap test result and the increased probability of being high risk HPV positive is potentially 
due to persistent infection of high risk HPV rather than differences in exposure to HPV 
52. This evidence provides good support for increased cervical cancer incidence in 
African American women. However, there does not seem to be any exploration into the 
connection of the high-risk HPV type and increased mortality rates of African American 
women with cervical cancer.  
Clifford, Franceschi, Diaz, Muñoz and Villa (2006) investigated the distribution of 
HPV type in women with and without cervical neoplastic diseases. After comparing a 
pooled analysis and a meta-analysis, the most common HPV types in invasive cervical 
cancer were HPV-16,-18,-33,-45,-31,-58,-52,-35,-59,-56,-51,-39,-68, and -73. The most 
common HPV types in high grade lesions (HSIL) were HPV-16, -31, -58, -18, -33, -52, -
35, -51, -56, -45, -39, -66 and -6. The most common HPV types in low grade lesions 
(LSIL) were HPV-16, -31, -51, -53, -56, -52, -18, -66 and -58. The most common HPV 
types in women with atypical squamous cells of undetermined significance (ASCUS) 
were not reportable because no meta-analysis on HPV type specific prevalence existed at 
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that time. The most common HPV types in women without cytological abnormalities 
were HPV-16, -42, -58, -31, -18, -56, -81, -35, -33, -45 and -52. The shifts in HPV type 
distribution across cervical lesions of increasing severity show that HPV types 16, 18 and 
45 are significantly more common in squamous cell carcinoma (SCC) than HSIL, HPV 
types 16 and 18 are more common in SCC than LSIL but other HPV types are more 
frequent in HSIL and LSIL than SCC. These differences indicate that HPV type can 
differ in the risk of developing cervical cancer from HSIL 53. This evidence provides 
good support for the distribution of HPV type related to LSIL, HSIL and cervical cancer. 
Their findings allow for inference of HPV types that may be connected to cervical cancer 
mortality. However, there does not seem to be any exploration into HPV type distribution 
by ethnicity. Even though geographical variations were taken into consideration, North 
America was not represented in the pooled analysis from the International Agency for 
Research on Cancer (IARC) but was stated to be similar to Europe in terms of proportion 
to HPV-16 infection. This clarification is important because a woman of African descent 
living in North America is different from a woman of African descent living in Europe.  
Therefore, based on the literature, early inflammatory responses may be critical for 
initiating a strong defense against HPV infection, however, there are genetic variants of 
immune responses. It has been shown that for African American women, the increased 
risk of an abnormal Pap test result and the increased probability of being high risk HPV 
positive is potentially due to persistent infection of high-risk HPV. Meanwhile, the cause 
for increased mortality among African American women with cervical cancer is 
unknown. For this reason, the identification of HPV type in African American women 
with cervical cancer is needed when investigating their death because HPV type can 
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differ in the development of cervical cancer even from HSIL. My hypothesis is that if the 
high-risk HPV types of African American women with cervical cancer were identified 
and cleared or prevented due to the improved efficacy of HPV vaccination, then their 
mortality rates would decrease. This is of particular interest because cervical cancer 
mortality rates are especially high in African American women in the rural South, but not 
for African American women in the West.  
For African American women in the South, some shared characteristics are that the 
poverty levels are above the national average, educational level is low, geographic 
isolation, lack of transportation, greater exposure to environmental and occupational 
hazards, poor housing, distrust of the government and mainstream medicine and a 
tenacity to sustain themselves in harsh living conditions50. Retrospective reviews of 
women diagnosed with cervical cancer indicate that 50% to 70% of them did not have a 
Pap test within five years prior to diagnosis or they never had been screened 50. Many 
women living in areas with high rates of cervical cancer mortality rely on publicly funded 
programs for their health care; therefore addressing cervical cancer mortality could serve 
as an indicator of an inefficient health care system concerning issues of medical care 
access, cultural issues, health communication and health education that 
disproportionately affect poor and underserved women.  Areas with high cervical cancer 
mortality also experience high mortality rates for breast cancer, colon cancer, heart 
disease, stroke, infant mortality and other conditions that improve with regular screening 
or early intervention 50. Because cervical cancer mortality is an avoidable cause of death, 
the overall health status of these geographic regions with high cervical cancer mortality 
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includes additional parameters of critical importance for improving the efficacy and 
delivery of HPV vaccination.  
2.6 Using Geospatial Data to Improve HPV Vaccine Delivery 
HPV vaccination data measurements associated with geographic locations are 
becoming more available from immunization registries. However, the fundamental nature 
of spatial data imposes some analytic challenges that should be considered with HPV 
vaccine delivery. When using spatial methods in epidemiologic research there are 
positive and negative aspects of spatial data that contribute to the accuracy of estimation. 
Measuring distance from one location to resources is frequently used to estimate 
environmental exposure. For example, the distance from a residence to a health 
department clinic or pharmacy to receive the HPV vaccine could be used to estimate 
environmental vaccination access. However, straight-line distance can be a poor proxy 
for estimating access if there are no direct roads or other means of traveling to a 
particular location54. 
When considering the relationship of spatial features geographical information 
systems (GIS) it is important to use topology. GIS topology is broadly defined as the 
spatial relationships between adjacent or neighboring features. Adjacency is a type of 
spatial relationship where two or more polygons share a side or a boundary. For example, 
Georgetown, Berkeley, Dorchester and Colleton counties are all adjacent to Charleston 
county. Neighborhood is a defined shape or area in which only the cells that have their 
cell centers within the neighborhood are considered part of the neighborhood. There 
should be no overlapping features. For example, a rectangle neighborhood can be created 
by specifying the height and width in map units such as degrees, meters or feet. So, in 
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measuring the neighborhood of Mt Pleasant, only include the land area of 116.8 km2 
would be included. Adjacency and neighborhoods are effective for modeling spatial 
relationships and the analyses of contiguity and connectivity. However, these data are 
inherently static and do not allow for real world representation of spatial changes over 
time. As a result, boundary problems such as edge effects must be considered. Edge 
effects are evidenced when the boundaries of a study area affect a given spatial 
measurement and lead to inaccurate estimates. This happens when the study area is 
defined by a border that does not prevent travel, therefore the geographic distribution of 
variables within an area may in fact extend beyond the border. Not accounting for edge 
effects introduces biases and under-reporting. For example, Berkley county may show a 
low count of administered HPV vaccination doses that they have administered, but this 
does not mean that fewer adolescents are receiving the HPV vaccine because in fact, 
many adolescents could be traveling to Charleston county to receive their vaccine55.    
Spatial autocorrelation measures the correlation of a variable with itself through 
space and refers to the relationship/pattern that variables of proximal entities will share 
more similar values than distant entities. It is expected that the level of spatial 
autocorrelation diminishes as a function of distance between two regions, unless there is 
some reason for similarity due to some other associated factor56. However, this assumes 
initial independence of data, which may not be appropriate. For example, the spatial 
autocorrelation between HPV vaccination rates in urban counties is assumed to be the 
same in the state of South Carolina. This would mean that the relationship between HPV 
vaccination rates was purely a function of distance between the counties and not relative 
to their location. Since a map is the representation of various locations, it can be defined 
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as a collection of spatially defined objects. The modifiable area unit problem (MAUP) is 
the inconsistency in how the map scale can yield different results when aggregated in 
different ways. Therefore, the changes the scale makes on the analysis needs to be 
quantified, otherwise variable measures could be underestimated. If results are 
significantly different, then the scale may need to be modified so that the results are more 
consistent. Scale refers to the ground area of the map and can be described as large or 
small. For example, a county level map of South Carolina is large scale representation 
compared to a state level map of South Carolina, which is small scale representation. 
When administered HPV vaccination doses are aggregated on a small scale (state level), 
areas with decreased HPV vaccination access are underestimated56. 
2.7 Insufficient Data  
Studies have shown that Immunization Information Systems also referred to as 
immunization registries, are effective in improving vaccination related activities to 
increase vaccination rates and reduce risk for vaccine preventable diseases4,57. However, 
in the literature there is a gap between national state level vaccination data and local level 
adolescent vaccination data often tracked by state immunization registries19,21,58–61. 
Hence, within state variability has not been commonly studied. Additionally, there is very 
little information about how vaccination is affecting the prevalence of HPV-associated 
cancers in rural areas. These areas may be medically underserved, have high rates of 
cervical cancer, and low rates of HPV vaccination20. The National Immunization Survey 
(NIS) provides data on HPV vaccination rates by state but there is less detailed 
information on the prevalence of HPV-associated cancers within states or how changing 
vaccination rates affects the prevalence of HPV-associated cancers directly in each 
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region. With the limitation of state level data, the reasons for geographic vaccination 
disparities are currently not well understood and this may be due to the lack of state 
immunization registry data at the local level. As a result, these local areas may continue 
to be a source of geographical disparities in HPV-associated cancer incidence as well 20. 
Therefore, more data are needed to evaluate impact of HPV vaccination in smaller 
geographic areas. With improved tools for HPV vaccination surveillance, the impact of 
county level vaccination programs and policies on population level vaccination and the 




3.0 SIGNIFICANCE & INNOVATION  
 
3.1 Clinical and Public Health Significance 
The occurrence of HPV associated cancers varies by cancer type, sex and 
race/ethnic group and is estimated to have a combined cost of $8 billion per year in the 
United States4. Approximately 44,000 new cases of HPV-associated cancers occur in the 
United States each year affecting women and men. HPV associated cancers most 
commonly occur in the cervix among women and in the oropharynx (back of the throat, 
including the base of the tongue and tonsils) among men62. Among these cancer types, it 
is estimated that 35,900 cancers (79%) were actually caused by HPV during 2011-2015 
and that 31,200 of these cancers could have been prevented by the 9-valent HPV 
vaccine62. However, as of 2019 no state in the United States has reached the Healthy 
People 2020 HPV vaccination goal of 80% coverage and HPV vaccination coverage 
varies substantially by state15,63.  
 The between state variation of HPV vaccination may be due to insufficient HPV 
surveillance. Unlike other reportable sexually transmitted infections in every state, HPV 
is not a nationally notifiable condition because HPV infections are too common. 
However, the delivery of HPV vaccinations is monitored. Frequently health-care claims 
data from adolescents and adults with employer-provided private health insurance in the 
United States are used to examine the population effectiveness of HPV vaccinations on 
HPV infections64. Additionally, in some states, all health care providers are required to 
report the administration of all vaccines to state immunization registries, however, the 
tracking and reporting of vaccine delivery is inconsistent among state health departments.  
A consistent source of data is the National Immunization Survey–Teen (NIS-Teen), 
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which is an annual survey that estimates vaccination coverage among adolescents aged 
13–17 years in the 50 states, the District of Columbia (DC), selected local areas, and 
territories. However, NIS-Teen data do not report HPV vaccination below the state level 
whereas state immunization registries are able to. Therefore, using state immunization 
registries is a critical step in overcoming the challenge of HPV vaccination surveillance 
beyond the state level. This research quantified HPV vaccination coverage at the county 
level using administered doses of the HPV vaccine collected by GA and SC state 
immunization registries. 
The clinical significance of monitoring HPV vaccination is that immunization 
coverage rates are a key indicator of overall community health65. The extent to which 
health departments deliver immunization services is associated with multiple components 
of quality public health services such as vaccine supply, surveillance, advocacy and 
communication and logistics. As a result, HPV vaccination coverage rates at the county 
level are impacted by the equity of access to health care services provided by health 
department clinics. Therefore, examining indicators of HD clinic access offers more 
insight into why HPV vaccination coverage rates differ by locality even though HDs 
implement many of the same immunization services. For example, HDs must conduct 
more quality assessment visits to providers enrolled in the VFC program. Nationally, 
under the VFC program, the Center for Disease Control (CDC) purchases vaccines at a 
discount and distributes them to grantees, such as state HDs and certain local and 
territorial public health agencies. These grantees distribute the vaccines at no charge to 
private physicians' offices and public health clinics that are registered as VFC providers. 
Because the federal government pays for the vaccine, providers are not paid for the cost 
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of the vaccine product. Instead, they are paid an administration fee for the costs that the 
provider incurs in administering the vaccine. For children enrolled in Medicaid, the 
Medicaid program pays the vaccine administration fee. For uninsured and underinsured 
children enrolled in VFC, the parents are billed for the administration fee and the 
administration fee varies by state66.  
3.2 Innovation 
GA and SC are both in public health region IV and therefore share the same 
regional office for programs and policies through the U.S. Department of Health and 
Human Services (HHS) (Figure 1). Despite the difference in the number of counties, GA 
and SC share similar population demographic characteristics67–69 (Figures 2, 3, Table 1). 
The estimated vaccination coverage rates in the public health region IV have shown GA’s 
Tdap and HPV vaccination rates to consistently be near or exceed the national average 
from 2016 to 2018. Conversely, during this same time period, SC was consistently below 
the national average with the lowest HPV vaccination coverage estimate in the United 
States in 2016 according to the National Immunization Survey – Teen data70. Systematic 
underuse of services that impact health by populations that share similar demographic 
characteristics may indicate a problem with equity of access11. Hence, access may be a 
significant driver of the different vaccination rates between GA and SC. To explore these 
differences at the county level GA has comprehensive adolescent HPV vaccination data 
available at the zip code level that can be aggregated to the county level using Zip Code 
Tabulation Areas but SC does not. Therefore, GA’s availability of county level HPV 
vaccination data and similar population demographics to SC, supports GA as a suitable 
model state for increasing SC’s HPV vaccination coverage rates.   
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This research innovatively 1) predicted county level HPV vaccination coverage 
using public health surveillance data previously collected by two different state 
immunization registries, census tracts and the department of transportation, instead of the 
exclusive use of national self-report surveys. With these data we 2) geographically 
characterized HPV vaccination coverage data at the county level using adolescents who 
have received the school mandated Tdap vaccine as the sample population. This sample 
population controlled for many sources of confounding such as parents who oppose 
vaccines, children with medical conditions preventing them from receiving vaccines, and 
those without any access to vaccines. This research 3) assessed indicators of health care 
access using health care utilization properties related to the health care settings 11: the 
number of public and private clinics and the number of health department clinics with 
VFC provider registration. This research 4) assessed indicators of health care access 
using a health care utilization property related to health equity71: public transit 
transportation. Using an adapted model of access to personal health care services from 
the Institute of Medicine (Figure 4) as our conceptual framework, this research 
innovatively 5) examined the effect of key factors associated with HPV vaccination to 
highlight counties with HD clinic access problems resulting in the poor health outcome of 
low HPV vaccination coverage. The mediators in this conceptual framework of provider 
recommendation, uptake and delivery of HPV vaccine and parental hesitancy were not 
adjusted for in analyses in order to examine the total effect and any effect of HPV 



























Table 1. Population Demographic Characteristics  
  Georgia South Carolina 
Counties 159 46 
HPV vaccination coverage trend:  
≥ 1 dose, all adolescents aged 13-17*  
(United States overall)* 
 
  
2016 (60.4 %) 67.30% 44.20% 
2017 (65.5 %) 64.30% 59.60% 
2018 (68.1 %) 68.10% 63.70% 
Tdap vaccination coverage trend:  
≥ 1 dose, all adolescents aged 13-17*  
(United States overall) 
 
  
2016 (88.0 %) 92.80% 77.50% 
2017 (88.7 %) 93.30% 89.40% 




Black/African American 31.30% 26.80% 
White 52.80% 63.80% 
Asian 4.20% 1.70% 
Hispanic 9.60% 5.70% 
American Indian/Alaskan Native 0.50% 0.50% 
Native Hawaiian/Other Pacific Islander 0.10% 0.10% 




Highschool graduation 81% 84% 




Median Household Income+ $56,100  $50,700  
Uninsured children+ 7% 4% 
Children in poverty+ 22% 22% 
Living in rural area+ 24.90% 33.70% 
 
Data Sources:  
* (Walker et al., 2019) 
+ (“County Health Rankings & Roadmaps,” 2019) 
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3.4 Figures   
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Objective: To characterize counties in GA by quantifying administered doses of the HPV 
and Tdap vaccines collected by the state health department immunization registry and 
indicators of HD clinic access. 
Methods: Using a cross sectional study design, secondary data were collected from 2010 
US Census, the Georgia Department of Public Health, Georgia Registry of Immunization 
Transactions and Services (GRITS), and the Georgia Department of Transportation for 
the years 2016 to 2018 for all 159 counties of GA. The study population was all male and 
female adolescents aged 13-17. The number of administered doses of the HPV vaccine 
and the number of administered doses of the Tdap vaccine were modeled in relation to 
number of private and public HD clinics, number of HD clinics registered in the VFC 
program and the availability of public transportation using Poisson regression, negative 
binomial regression and Bayesian spatial analysis. 
Results: Choropleth maps showed similar clustering patterns between administered doses 
of the HPV vaccine and Tdap vaccine and increased counts of administered vaccine 
doses in counties with both public and private clinics. Administered doses of HPV 
vaccine were found to exhibit spatial dependence across counties. Accounting for spatial 
dependence, the availability of public transit has a significant positive effect on 
administered doses of HPV vaccine. Administered doses of the Tdap vaccine were also 
found to exhibit spatial dependence across counties. Accounting for spatial dependence, 
the number of private health department clinics has a significant positive effect on 
administered doses of the Tdap vaccine.  
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Conclusions: This study calls attention to the need for maps at the county level to show 
vaccination variability and clustering patterns to provide additional insights on the access 
to health care. Using Bayesian spatial models to account for the effect of spatial 
variability on HPV vaccine and Tdap vaccine dose administration between counties 
changed the significant effects of HD clinic access on HPV vaccine and Tdap vaccine 
dose administration to non-significant. This suggests that spatial statistical models are 
needed to accurately identify and estimate factors associated with administering doses of 
the HPV and Tdap vaccines. Future work is needed to further examine the utilization of 
HPV vaccination services among urban groupings.  
 






In its 2012-2013 report, the President’s Cancer Panel concluded that underuse of 
human papilloma virus (HPV) vaccines was a serious but correctable threat to progress 
against cancer1,2. Approximately 91% of cervical and anal cancers, 75% of vaginal, 69% 
of vulvar, 70% oropharyngeal cancers, and 63% of penile cancers are the result of an 
HPV infection3,4. During 2012-2016, an estimated average of 34,800 HPV-attributable 
cancers were diagnosed each year. Among these estimated cancers, 92%  were 
attributable to the HPV types that are included in the 9-valent HPV vaccine and could 
have been prevented if HPV vaccine recommendations were followed5. The 9-valent 
vaccine, Gardasil 9, was studied in clinical trials with more than 15,000 females and 
males and found to be safe and effective6. Currently, the HPV vaccination coverage rate 
is increasing at national and state levels. As of 2019, about half of U.S. adolescents aged 
13-17 are fully vaccinated (54.2%) and 71.5 % of them have received at least one dose of 
the HPV vaccine7. At the state level, South Carolina has impressively improved from a 
rate of 44.2% in 2016 for adolescents receiving at least one dose of the HPV vaccine, 
which was substantially below the national average of 60.4% (44.2%) to matching the 
national average (71%) in 20197. However the overall national goal is to increase HPV 
vaccination coverage levels for adolescents to 80%8.   
Efforts to increase HPV vaccination are supported by resources often 
administered and utilized at the county level through state Health Departments (HD) such 
as childhood and adolescent vaccinations administered by school nurses and at public or 
private health clinics, community education and outreach, vaccine program enrollment, 
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and immunization registry reporting. Health care utilization can be determined by 
whether the provided health care can be accessed9. Access to health resources and quality 
healthcare services is an important determinant of health 10 and certain barriers such as 
physician shortage, lack of transportation, and insurance coverage can make gaining 
access difficult. Therefore, the underutilization of the HPV vaccine may be due to 
inequitable access. Equitable access to health care requires that everyone is able to 
receive an adequate level of care and resources without excessive burdens11.  
Maximizing access to HPV vaccination service was quantified as 80% 
vaccination coverage by Healthy People 202012. As of 2019 no state in the United States 
reached the Healthy People 2020 HPV vaccination target of 80% coverage and HPV 
vaccination coverage varies substantially by state7,12,13. The between state variation of 
HPV vaccination may be due to the absence of standardized monitoring of HPV 
infections. Unlike other reportable sexually transmitted infections in every state, HPV 
infections and most HPV-associated conditions are not nationally notifiable14. Since HPV 
infections are too common to be reportable, making HPV-associated conditions 
reportable would increase the extent of public health surveillance which is useful for 
measuring the need and effect of HPV vaccination interventions and for targeting 
resources. Instead, health-care claims data from adolescents and adults with employer-
provided private health insurance in the United States are used to examine the population 
effectiveness of HPV vaccinations on HPV infections15. The HPV vaccine is also not a 
required immunization for school attendance like the Tetanus, diphtheria, and pertussis 
(Tdap) vaccine. Therefore, strategically allocating HD resources is necessary to improve 
HPV vaccination coverage16 and address the President’s Cancer Panel’s third goal of 
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maximizing access to HPV vaccination services1. An essential tool for allocating HD 
resources is the state immunization registry. GA’s state HD immunization registry has a 
surveillance system that is able to monitor at the county level how many of their clinics 
are public, private, registered with the Vaccine For Children (VFC) program and the 
administered doses of the HPV and Tdap vaccine per clinic. This has contributed to 
Georgia’s vaccination coverage trend of adolescents receiving at least one dose of the 
HPV vaccine staying close to the national average since 201613 (Table 1). However, 
some states to do not have county level HPV vaccination coverage data available and this 
is a major obstacle to effectively monitor HD resource utilization to increase HPV 
vaccination.  
Therefore, the objective of this study was to characterize counties in GA by 
quantifying administered doses of the HPV and Tdap vaccines collected by the state HD 
immunization registry and indicators of HD clinic access. The rationale is based on the 
ability to evaluate the county level geospatial distribution of administered HPV vaccine 
doses compared to administered Tdap vaccine doses with indicators of HD clinic access 
to better understand county level access to adolescent HPV vaccination. The hypothesis 
is that in GA, administered doses of the HPV vaccine and the Tdap vaccine are associated 
with indicators of HD clinic access.   
5.3 Methods  
Data 
Using a cross sectional study design, secondary data were collected from 2010 US 
Census, the Georgia Department of Public Health, Georgia Registry of Immunization 
Transactions and Services (GRITS), and the Georgia Department of Transportation for 
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the years 2016 to 2018 for all 159 counties of GA. The study population was all male and 
female adolescents aged 13-17 in GA. Differences in HD clinic access in relation to 
administered doses of HPV and Tdap were assessed. Indicators of HD clinic access were 
defined as the number of available public and private clinics, the number of HD clinics 
with Vaccine For Children (VFC) provider registration, and the availability of public 
transportation in the county. Administered doses were defined as greater than or equal to 
one vaccine dose given to adolescents aged 13 -17 from public and private clinics sites 
regardless of their VFC program participation and reported to the state immunization 
registry. The number of administered HPV and Tdap vaccine doses, the number of public 
and private HD clinics, and the number of clinics registered in the VFC program were 
collected by zip code and aggregated to the county level using Zip Code Tabulation 
Areas (ZCTAs). The availability of public transportation was defined by the presence of 
public transit routes inclusive of the metro Atlanta region, only rural, only urban, both 
rural and urban, and city only transit identified in each county by the Georgia Department 
of Transportation. Choropleth maps17 of administered HPV and Tdap vaccine doses and 
indicators of access to HD clinics at the county level were created SAS statistical 
software version 9.4 18.   
Statistical Modeling & Analyses 
Two dependent variables were individually modeled as outcomes: the number of 
administered doses of the HPV vaccine and the number of administered doses of the 
Tdap vaccine. These dependent variables were modeled in relation to the explanatory 
variables defined as indicators of HD clinic access: number of private and public HD 
clinics, number of HD clinics registered in the VFC program and the availability of 
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public transportation. For both outcomes three statistical methods were used: Poisson 
regression, negative binomial regression and Bayesian spatial analysis. While exploring 
the data with Poisson regression, overdispersion was detected so negative binomial 
regression was used for modeling19. Fixed effects only were evaluated first, and a 
backward stepwise selection method for selection of explanatory variables via the Akaike 
Information Criterion (AIC). To account for the non-spatial random effect of county, 
random intercept negative binomial models were evaluated using backward stepwise 
selection via AIC. Initially, the model was fit maintaining all the explanatory variables. 
The final model retained all variables that were statistically significant at p<0.05. 
Likelihood ratio tests were used to compare models, with the best model fit determined 
by AIC.  
Systematic spatial variation also known as spatial autocorrelation in the counts of 
administered doses of the HPV vaccine and the Tdap vaccine were assessed using  
Moran’s I20. Positive values of Moran’s I indicate that nearby counties tend to exhibit 
similar counts of administered HPV and Tdap vaccine doses, while negative values 
indicate dissimilar counts. In the data used for this study the existence of a significant 
spatial autocorrelation points to the necessity of using Conditional autoregressive (CAR) 
models to represent this spatial autocorrelation21. CAR models smooth noisy estimates by 
pooling information from neighboring regions. A proportion of this spatial 
autocorrelation may be modeled by known covariate risk factors in a regression model, 
but it is common for spatial structure to remain in the residuals after accounting for these 
covariate effects. This residual spatial autocorrelation can be influenced by unmeasured 
confounding, neighborhood effects, and grouping effects. The most common remedy is to 
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augment the linear predictor with a set of spatially autocorrelated random effects, as part 
of a Bayesian hierarchical model. These random effects are typically represented with a 
conditional autoregressive prior, which generates spatial autocorrelation through the 
adjacency structure of the areal units21. 
 For the spatial analysis two Bayesian models were compared: Besag-York-Mollié 
(BYM)22 and Leroux23 with Poisson family distributions. The BYM model uses a 
parameter for structured spatial random effects and a parameter for unstructured spatial 
random effects to account for over-dispersion not modelled by the Poisson variates. 
When the observed variance is not fully explained by the spatial structure of the data, the 
independent error term will account for the rest24. However, the BYM model only 
assumes a spatially structured component, so the spatial and non-spatial random effects 
cannot be identified independently from each other. This results in the non-spatial 
random error or pure overdispersion being modelled as spatial correlation25. The Leroux 
model is a variation of the BYM and CAR models in which there is only one spatial 
random effect parameter for each area that includes characteristics of both structured and 
unstructured spatial random effects26. For this illustration, the random effect terms can be 
interpreted as the county effect on HPV vaccine and Tdap vaccine dose administration. 
To find the best fitting Bayesian model the Deviance Information Criterion (DIC) 
was used. Each spatial model was run to convergence based on multiple chain diagnostics 
using the Brooks-Gelman-Rubin statistics27. In the converged sample DIC was 
monitored. Convergence usually took place within 1,000 iterations and inference was 
based on a chain length of 1,000 after convergence. Regression analyses and estimation 
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of the model parameters carried out with MCMC simulation techniques were 
implemented in R V.3.6.3 software packages28. 
5.4 Results  
Data Maps 
Choropleth maps are thematic maps in which areas are colored or patterned to 
indicate differences of quantity in those areas17. In this study they show the geospatial 
distribution of the aggregated counts of administered does of the HPV vaccine and Tdap 
vaccine, counts of HD private clinics, counts of HD public clinics, and access to public 
transportation for each county (Figures 1-5). The clustering patterns of administered 
doses of the HPV vaccine and the Tdap vaccine are both similar with increased counts in 
the Atlanta (ATL) region. There is not a defined clustering pattern with the quantity of 
administered vaccine doses in counties with access to public transportation. However, 
there is a pattern of increased counts of administered vaccine doses in counties with both 
public and private clinics.  
HPV Outcome 
The fixed effects negative binomial model was fit maintaining all of the 
explanatory variables. None of the indicators of HD access variables were statistically 
significant at p-values less than 0.05. The non-spatial random intercept negative binomial 
model, to account for correlations within county, was fit initially with all of the 
explanatory variables. The variable of HD clinics registered in the VFC program was 
highly correlated with private HD clinics (r = -0.961) and therefore dropped from the 
model. The remaining explanatory variables of private HD clinics, public HD clinics and 
the availability of public transportation were all statistically significantly associated with 
54 
 
counts of administered HPV doses (Table 2). These estimates can be interpreted as 1) a 
one unit increase in the number of private HD clinics increases the expected counts of 
administered doses of HPV vaccine by 1.08 times for adolescents in the same county and 
holding all other variables in the model constant; 2) a one unit increase in the number of 
public HD clinics increases the expected counts of administered doses of HPV vaccine by 
1.17 times for adolescents in the same county and holding all other variables in the model 
constant; and 3) having access to public transportation increases the expected counts of 
administered doses of HPV vaccine by 1.63 times for adolescents in the same county  
compared to not having access and holding all other variables in the model constant. 
Using Moran’s I, the hypothesis that the administered doses of the HPV vaccine 
are randomly distributed across counties following a completely random process was 
rejected at the 0.05 level of significance. Thus, suggesting that the spatial distribution of 
administered HPV vaccine doses are more spatially clustered than would be expected if 
the underlying spatial distribution was random. Figure 6 shows a scatter plot of the 
average sum of total administered doses of HPV vaccine for each county and Moran's I 
coefficient (I=0.393) as the slope of the line. The positive (upward) slope suggests that as 
the sum of administered HPV vaccine doses of a county increases, so does the sum of its 
neighboring counties.  
Using the statistically significant explanatory variables in the negative binomial 
random effect model, comparison of the different Bayesian models showed the Leroux 
model was the best model (DIC = 1783.6). From the Leroux model posterior estimates 
for the parameters and measures of interest were obtained, including medians and 95% 
credible intervals. Estimates for the best-fitting Leroux CAR model are shown in Table 3. 
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Since the Leroux model showed evidence of convergence via the Potential Scale 
Reduction Factor (PSRF) of 1.2 with Gelman and Rubin's Convergence Diagnostic, it can 
be inferred that the availability of public transit has a significant positive effect on 
administered doses of HPV vaccine and that there is no significant effect of private HD 
clinics, and Public HD clinics on increasing administered doses of HPV vaccine. 
Tdap Outcome 
With the fixed effects negative binomial model, it was initially fit maintaining all 
of the explanatory variables. In that analysis, only the number of private HD clinics was 
statistically significant with a p-value less than 0.05. However, to account for correlations 
within county, a non-spatial random effect negative binomial model was fit using all 
explanatory variables. The number of HD clinics registered in the VFC program was 
highly correlated with the number of private HD clinics (r = -0.976) and therefore 
dropped from the model. Of the remaining explanatory variables, the number of private 
HD clinics and access to public transit remained statistically significant (Table 2). These 
estimates can be interpreted as a one unit increase in the number of private HD clinics 
increases the expected counts of administered doses of Tdap vaccine by 1.09 times for 
adolescents in the same county and holding all other variables in the model constant. 
Similarly, having access to public transportation increases the expected counts of 
administered doses of Tdap vaccine by 1.38 times for adolescents in the same county and 
holding all other variables in the model constant. The best negative binomial regression 
model was the fixed effect model (AIC = 2630.12) (Table 2). However, a likelihood ratio 
test comparing the final fixed effects and the final random intercept model showed that 
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the random intercept model is statistically more beneficial with the access to public 
transit variable and the county effect included (p-value = 0.004). 
Using Moran’s I, the hypothesis that the administered doses of the Tdap vaccine 
are randomly distributed across counties following a completely random process was 
rejected at the 0.05 level of significance. Thus suggesting that the spatial distribution of 
administered Tdap vaccine doses are more spatially clustered than would be expected if 
the underlying spatial distribution was random.  Figure 7 shows a scatter plot of the 
average sum of total administered doses of Tdap vaccine for each county and Moran's I 
coefficient (I =0.4107) as the slope of the line. The positive (upward) slope suggests that 
as the sum of administered Tdap vaccine doses of a county increases, so does the sum of 
its neighboring counties.  
Using the statistically significant explanatory variables in the negative binomial 
random intercept model, comparison of the different Bayesian models showed the Leroux 
model to be the best model (DIC = 1710.35). From the Leroux model posterior estimates 
for the parameters and measures of interest were obtained, including medians and 95% 
credible intervals (Table 5). Since the Leroux model showed evidence of convergence via 
the Potential Scale Reduction Factor (PSRF) of 1.3 with Gelman and Rubin's 
Convergence Diagnostic, it can be inferred that there is significant positive effect of the 
number of private HD clinics on increasing administered doses of Tdap vaccine, and the 






5.5 Discussion   
Interpretation 
In this study the counties of GA were characterized based on the quantity of 
administered doses of the HPV vaccine, the Tdap vaccine and indicators of HD clinic 
access using choropleth maps. Mapping county level counts provides greater 
understanding of the trends and variability in patterns not possible by examination of 
direct national and state level estimates. This was shown with no clustering pattern of 
administered doses across counties with public transit services. These results are novel in 
showing HPV and Tdap vaccination variability at the county level. Also, at the county 
level there were clustering patterns of higher counts of administered vaccine doses in the 
ATL region. These results were expected and support a common vaccination trend often 
seen at the state level due to the large urban demographic. Additionally, mapping county 
level vaccine counts can help highlight areas where HPV and Tdap vaccination coverage 
may be higher or lower than the national average and provide additional insights on the 
access to health care. This was shown with the clustering pattern of increased counts of 
administered doses in counties with both public and private clinics. This pattern is 
expected since health care services can be provided through public and private providers 
serviced by the HD. Public health care is usually provided by the government through 
national healthcare systems. Private health care can be provided through for profit 
hospitals and self-employed practitioners, and “not for profit” non-government providers, 
including faith-based organizations.29 However, our results also show that there was a 
clustering pattern of less administered doses of HPV and Tdap vaccines in counties 
where there were fewer private health clinics. These results suggest further examination 
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into the number of HPV and Tdap vaccines ordered from public and private health clinics 
serviced by the HD to clarify the reduced number of administered vaccine doses. 
The patterns seen in our maps were supported by our statistical analyses. Both 
administered doses of the HPV vaccine and the Tdap vaccine were significantly 
associated with indicators of HD clinic access. However, to account for extra uncertainty 
and inherent spatial autocorrelation, Bayesian spatial models were used because 
administered doses of the HPV vaccine and the Tdap vaccine were found to exhibit 
strong spatial dependence. Using these models to account for the effect of spatial 
variability on HPV vaccine and Tdap vaccine dose administration between counties 
changed the significant effects of HD clinic access on HPV vaccine and Tdap vaccine 
dose administration to non-significant. This suggests that spatial statistical models are 
needed to accurately identify and estimate factors associated with administering doses of 
the HPV and Tdap vaccines in GA.  
In relation to public health efforts, HPV vaccination coverage is lower than Tdap 
vaccination coverage at the national and state level. This study showed that the inclusion 
of the spatial random effect at the county level explains additional differences in HPV 
and Tdap vaccine dose administration. Specifically, these results indicate that spatial 
variability between counties and public transit access affect HPV vaccine dose 
administration. Whereas, spatial variability between counties and the number of HD 
private clinics affect Tdap vaccine dose administration. Therefore, public health 
practitioners should be attentive to the differences and similarities of resources and 
demographics between counties. These results are similar to previous studies that found 
that HPV vaccination rates vary geographically30. Other studies have also demonstrated 
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that HPV vaccination has a strong spatial dependence when identifying and estimating 
factors associated with HPV vaccine uptake16 and that spatial accessibility to vaccination 
providers increases overall vaccination31. Our results differed from a previous study that 
found overall geographic access measures of travel distance and public transportation to 
clinics were not significantly associated with vaccine initiation32. However, this 
difference may be due to the limitation of the study sample to an urban area.    
Limitations 
There are limitations to acknowledge in this study. First, not all clinic sites are 
represented because not all providers administer vaccinations, but these data do represent 
all clinics who offer vaccination. Administered vaccine doses are only from clinic sites 
that report to the state’s immunization registry. As such, there may be vaccination doses 
administered that are not accounted for and would result in an underestimation of HPV 
and Tdap vaccination delivery and coverage. Second, with administered dosing data is 
that it is not possible to differentiate whether a dose was given to initiate or complete an 
HPV vaccination series due to the fact that the immunization registry is not linked with 
vital records. However, there are also several strengths to this study. This study is one of 
the first studies to look at the aggregated counts of HPV vaccine and Tdap vaccine dose 
administration at the county level as a proxy measure of HPV vaccination coverage. 
These county level maps can used by practitioners and public health officials as baseline 
visuals for further investigation of where clinics are not administering doses of the HPV 
and Tdap vaccines. These results highlight where additional resources from HDs in GA 
may be needed to improve the administration of HPV vaccination. Additionally, these 
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results can be generalized to other states that have similar decentralized governance 
structures like GA because of how vaccination health resources are administered.   
Conclusion 
Overall, reaching 80% HPV vaccination coverage among U.S. adolescents is an 
attainable goal. However more information is needed beyond data at the national and 
state level. This study showed the importance of considering spatial variation at the 
county level when investigating HPV and Tdap vaccine dose administration. Mapping 
spatial patterns provides a visual context to data that is helpful for informing the 
development of public health interventions and guiding the provision of health services. 
Additionally, mapping data can be useful as an advocacy tool for documenting how poor 
public health infrastructure contributes to poor health outcomes to support improving 
healthcare administration and public health infrastructure.   
The need for public health interventions focused on HPV vaccination was 
emphasized in early 2020 when the coronavirus disease 2019 (COVID-19) pandemic 
changed the way health care providers operate and provide routine and essential 
vaccination services. Like dose administration, vaccine orders are another proxy measure 
for vaccination coverage33. Examination of VFC provider ordering data showed that 
vaccine orders for HPV vaccine and Tdap vaccine decreased in mid-March when 
COVID-19 was declared a national emergency. Therefore, public health interventions to 
ensure that routine vaccination services for adolescents are maintained is essential to 
continue progress in protecting communities7. To do so, future work is need with small 
area studies. The collection of data at local levels such as ZIP code could help pinpoint 
areas with the greatest disparities in HPV vaccination and inform the development of 
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targeted interventions for these populations. Also, as seen with our results in the ATL 
region, large populated urban regions have high HPV and Tdap dose administration. So 
comparing the utilization of HPV vaccination services among urban groupings like 
metropolitan geographic areas, inner cities of large metropolitan areas, fringes of large 
cities also known as suburbs, and small metropolitan areas could help examine the 
sensitivity of spatial modeling strategies in estimating within county HPV vaccine dose 






















Table 1. HPV & Tdap Vaccination Coverage Trends 
 Georgia 
Counties (n) 159 
HPV vaccination coverage trend: 
≥1 dose, all adolescents aged 13-17 
(United States overall) 
 
2016 (60.4%) 67.3% 
2017 (65.5%) 64.3% 
2018 (68.1%) 68.1% 
2019 (71.5%) 65.9% 
Tdap vaccination coverage trend: 
≥1 dose, all adolescents aged 13-17 
(United States overall) 
 
2016 (88.0%) 92.8% 
2017 (88.7%) 93.3% 
2018 (88.9%) 94.2% 
2019 (90.2%) 92.5% 
  
Data Sources: TeenVaxView | 2008-Present Adolescent HPV 
Vaccination Coverage Trend Report | CDC and Elam-Evans LD, 
Yankey D, Singleton JA, et al. National, Regional, State, and 
Selected Local Area Vaccination Coverage Among Adolescents 
Aged 13–17 Years — United States, 2019. MMWR Morb Mortal 
Wkly Rep. 2020 
 
Table 2.  Association of administered HPV vaccine doses and indicators of 
HD clinic access 
Random intercept 
model 
estimate Exp(estimate) P- value 
Intercept 5.915 370.77 < 2e-16 
Private HD clinics 0.088 1.08 < 2e-16 
Public HD clinics 0.153 1.17 3.51 e-08 






Table 3.  Posterior results for the parameter estimates of the Leroux model:  
 
administered doses of HPV vaccine ~ Private HD clinics + Public HD clinics + 
public transit 
 
HPV vaccine parameters median 2.5% 97.5% 
Intercept 6.270 5.63 8.91 
Private HD clinics 0.066 -0.11 0.15 
Public HD clinics -0.056 -1.00 0.20 
Public transit access 0.423 0.12 0.80 
Table 4.  Association of administered Tdap vaccine doses and indicators of HD 
clinic access 
Fixed effects model 
(AIC = 2630.12) 
estimate Exp(estimate) P- value 
Intercept  6.46 638.35 < 2e-16 
Private HD clinics 0.14 1.15 < 2e-16 
    
Random intercept 
model 
(AIC = 2645.3) 
estimate Exp(estimate) P- value 
Intercept 5.97 393.52 < 2e-16 
Private HD clinics 0.08 1.09 < 2e-16 
Public transit access 0.32 1.38 7.39e-09 
Table 5.  Posterior results for the parameter estimates of the Leroux model:  
 
administered doses of Tdap vaccine ~ Private HD clinics + public transit 
 
Tdap vaccine parameters median 2.5% 97.5% 
Intercept 6.036 5.34 6.50 
Private HD clinics 0.087 0.033 0.16 
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6.1 Abstract  
Objective: To predict the association between HPV vaccination coverage and health 
department clinic access in GA at the county level among Tdap vaccinated adolescents. 
Methods: Using a cross sectional study design, secondary data were analyzed from 2019 
American Community Survey 5 year estimates, the Georgia Department of Public Health, 
Georgia Registry of Immunization Transactions and Services (GRITS), and the Georgia 
Department of Transportation for the years 2016 to 2018 for all 159 counties of Georgia. 
The study population was male and female adolescents aged 13-17 who received their 
Tdap and HPV vaccines in Georgia. Prediction models were developed using 2016-2017 
data and predictions were validated using 2018 data. The number of administered HPV 
vaccine doses and the HPV vaccination coverage rates were modeled using indicators of 
heath department clinic access and age, sex, race/ethnicity, socioeconomic status, 
education, median household income, health insurance and resident type.  
Results: The prediction model for counts of administered HPV vaccine doses showed 
statistical significance and a positive association with indicators of HD clinic access: 
public transit and the number of HD private clinics. The prediction model for HPV 
vaccination coverage rate accounted for Tdap vaccinated adolescents and was a better fit. 
The prediction model for HPV vaccination coverage rate showed statistical significance 
and a negative association with the variables of White race and rural residency. 
Conclusion: Using data from adolescents who have received the Tdap vaccine as a 
sample population established access to vaccines and controls for multiple confounders 
such as vaccination ineligibility, vaccine exemption, and adolescents with parents 
opposed to vaccination. Therefore, within this population, rural counties and the White 
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racial category were identified as significant predictors of a decrease in HPV vaccine 
dose administration. Epidemiologists, program planners and health educators could use 
these data to target HPV vaccination efforts among non-Hispanic whites and in rural 
communities. Future work is needed with the use of geographically weighted regression 
models to improve predictions of HPV vaccination by accounting for spatial dependence 
in addition to overdispersion because this could incorporate the variability for other 
unmeasured factors. 
Keywords:  HPV vaccine, Tdap vaccine, prediction models, small area estimation  
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6.2 Introduction  
The equity of access to health care services such as health screening services, 
public health nursing, the number of clinics, health education, immunization services and 
school health services at the county level significantly impacts Human Papillomavirus 
(HPV) vaccination coverage rates. A key indicator of overall community health is 
immunization coverage rates and vaccination coverage is the traditional metric used to 
assess vaccine usage; however, provider orders and doses administered represent two 
immediately available proxy measures1. State immunization resources and immunization 
service delivery through the Health Department (HD) are organized at the county level or 
local level2. Three indicators of access related to local Health Department clinics of 
particular interest are the number of public and private health clinics, Vaccine For 
Children (VFC) provider registration and the availability of public transportation. Public 
transportation is health equity metric related to community determinants of health. Some 
urban and rural communities are disproportionately affected by the access to a vehicle 
which then impacts their access to health care services3.   
Another metric of access is the affordability of services. Under the Vaccine for 
Children (VFC) program, the Center for Disease Control (CDC) purchases vaccines at a 
discount and distributes them to grantees, such as state HDs and certain local and 
territorial public health agencies. These grantees distribute the vaccines at no charge to 
private physicians' offices and public health clinics that are registered as VFC providers. 
Because the federal government pays for the vaccine, providers are not paid for the cost 
of the vaccine product. Instead, they are paid an administration fee for the costs that the 
provider incurs in administering the vaccine. For children enrolled in Medicaid, the 
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Medicaid program pays the vaccine administration fee. For uninsured and underinsured 
children enrolled in VFC, the parents may be billed for the administration fee and the 
administration fee varies by state4. While this fee is rarely pursued in the event of non-
payment, this practice could introduce a perceived barrier to vaccine access.  
Georgia’s (GA) state HD immunization registry has a surveillance system that is 
able to monitor at the county level how many of their clinics are public, private, 
registered with the Vaccine For Children (VFC) program and the administered doses of 
the HPV vaccine per clinic. Additionally, GA’s vaccination coverage trend of adolescents 
receiving at least one dose of the HPV vaccine has stayed close to the national average 
since 20165. However, persistent differences in HPV vaccination uptake have been 
observed among adolescents who receive the Tetanus, diphtheria, pertussis (Tdap) 
vaccine5,6. Even though the Tdap vaccine is school mandated, states with HPV vaccine 
mandates have similar rates of HPV vaccination as those without mandates, thus 
indicating that the underlining difference for vaccination uptake are not fully understood 
7,8.  
With equity of access to health services, there should be no differences in 
vaccination coverage by race, ethnic origin, income, geographical location or insurance 
status9, yet HPV vaccine coverage rates vary by geographic location and other factors 
despite similar programing and activities provided by HDs10. Prior studies have identified 
factors at the local level associated with HPV vaccination coverage as the uptake of other 
adolescent vaccines, gender, race/ethnicity, socioeconomic status, religiosity, political 
ideology, education policies and insurance status7,11,12. However, the systematic underuse 
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of immunization services by populations that share characteristics, such as education or 
attitudes, indicates a problem with equity of access9.  
 Since data have shown Tdap vaccination rates to surpass HPV vaccination rates, 
these adolescents are a prime target group for increasing HPV vaccinations. Therefore, 
the objective of this study was to predict the association between HPV vaccination dose 
coverage and HD clinic access in GA at the county level among Tdap vaccinated 
adolescents. The rational for this study was that using adolescents who have received the 
Tdap vaccine as a sample population establishes access to vaccines and controls for 
multiple confounders such as vaccination ineligibility, vaccine exemption, adolescents 
with parents opposed to vaccination and no access to vaccination services. Also, prior 
studies that have examined factors associated with low HPV vaccination did not include 
HD level variables. Therefore, this study contributes to the literature by incorporating 
new variables of HD clinic access as potential explanatory factors that significantly 
impact HPV vaccination dose administration at the county level. The hypothesis is that 
significant factors associated with HPV vaccine dose administration will be predicted 
among Tdap vaccinated adolescents at the county level in GA.  
6.3 Methods 
Data  
Using a cross sectional study design, secondary data were analyzed from the 2019 
American Community Survey 5 year estimates, the Georgia Department of Public Health, 
Georgia Registry of Immunization Transactions and Services (GRITS), and the Georgia 
Department of Transportation for the years 2016 to 2018 for all 159 counties of 
Georgia. Data from years 2016 – 2017 were used to develop the predictive models and 
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data from year 2018 were used to validate the predictive models. The study population 
was male and female adolescents aged 13-17 who received their Tdap and HPV vaccines 
in Georgia. The number of administered Tdap vaccine doses was used as a proxy 
measure for population who received the Tdap vaccine because adolescent Tdap is a 
single dose vaccine with a booster every ten years recommended for those who get it in 
the 13-18 age group. Predictor variables included indicators of access to HD clinics 
defined as the counts of public and private clinic sites, counts of clinic sites with Vaccine 
For Children (VFC) provider registration, and the availability of public transit routes. 
These variables were collected by zip code and aggregated to the county level using Zip 
Code Tabulation Areas (ZCTAs) for years 2016 - 2017 and then for 2018. Table 1 shows 
additional predictor variables selected as factors associated with HPV vaccination based 
on previous literature review were age (percent under 18 years) , sex (percent of total 
population), race/ethnicity (percent of population), socioeconomic status (percent below 
poverty level under 18), education (high school graduate or higher percentage), median 
household income, health insurance (percent uninsured and insured under age of 19 
years) and resident type (urban and rural percentage). The education variable includes 
high school graduate equivalency, some college – no degree, associate’s degree, 
bachelor’s degree and graduate or professional degree.  
Statistical Modeling & Analyses  
Two predictive models were developed: one with a count outcome of the number 
of administered HPV vaccine doses and the other, a rate outcome of HPV vaccination 
dose coverage. The HPV vaccination dose coverage rate was calculated as the number of 
HPV vaccination doses administered among the number of adolescents who have 
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received the Tdap vaccine. The number of adolescents who received the Tdap vaccine in 
years 2016 and 2017 was modeled as an offset variable, (i.e. constant term) on the log 
scale to convert the number of administered HPV and Tdap vaccine doses to population-
adjusted rates. The relationship between exposure variables and both outcomes were 
assessed using univariate analysis. While exploring the data with Poisson regression, 
overdispersion was detected so negative binomial regression was used to model13 both 
outcomes. Distributional assumptions were tested and asserted. Final prediction models 
were selected based on the statistical significance of informative predictors using alpha 
0.05 and the Akaike Information Criterion (AIC) statistic.  
The beta coefficients of the final developed models were then applied to the 
external data from 2018. To evaluate prediction model performance the Root Mean 
Square Error (RMSE) and coverage probabilities with 95% prediction intervals for model 
calibration (i.e. agreement between observed outcomes and predictions)14,15 were 
calculated. The comparative size of RMSE indicates model fit of how close the observed 
data points are to the model’s predicted values. Hence a smaller RMSE value indicates 
that the prediction model is better at predicting the observed data. Coverage probabilities 
with a 95% prediction interval for administered doses of the HPV vaccine should include 
the true value of administered dose of the HPV vaccine approximately 95% of the time. 
Univariate and bivariate analyses were done in SAS statistical software version 9.4 16. 




6.4 Results  
Dose Count Outcome Prediction Model 
The prediction model for the number of HPV vaccine administered doses was 
initially fit maintaining all of the predictor variables. Several of the predictor variables 
were statistically significantly associated with the number of HPV vaccine administered 
doses: rural residency, education, poverty, age, Asian, Hispanic, public transit and HD 
private clinics (Table 2). These estimates are interpreted individually holding all the other 
variables constant: 1) a one percent increase in rural residency decreases the number of 
HPV vaccine administered doses by 0.03%. 2) A change from no to yes in access to 
public transit increases the number of HPV vaccine administered doses by 1.32%. 3) An 
increase of one HD Private clinic increases administered doses of the HPV vaccine by 
1.04%. The remaining estimates can be interpreted similarly. After applying the final 
developed count model to 2018 data, the coverage probability of model calibration was 
86.8% and can be interpreted as the probability that the prediction interval contains the 
true values of HPV vaccine administered doses approximately 87% of the time.  
Dose Coverage Rate Outcome Prediction Model 
The HPV vaccination dose coverage rate prediction model was initially fit 
maintaining all of the predictor variables. Two of the predictor variables were statistically 
significantly associated with the number of administered doses of HPV vaccine among 
adolescents who received the Tdap vaccine: rural resident type and the White racial 
category (Table 3). These estimates are interpreted individually holding all the other 
variables constant: 1) a one percent increase in rural residency decreases the HPV 
vaccine dose coverage rate by 0.72%. 2) A one percent increase in White racial category 
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decreases the HPV vaccine dose coverage rate by 0.51%. After applying the final 
developed rate model to 2018 data, the coverage probability of model calibration was 
98.1% and can be interpreted as the probability that the prediction interval contains the 
true values of HPV vaccine dose coverage rates approximately 98% of the time.  
6.5 Discussion 
Interpretation 
 In this study two prediction models were developed from 2016 and 2017 
data, one using counts of administered HPV vaccine and the other using an HPV 
vaccination dose coverage rate. Both were validated using counts of administered HPV 
vaccine doses from year 2018. Both models used demographic data and indicators of HD 
clinic access as predictors at the county level. Both models at the county level predicted 
statistically significant factors of HPV vaccine dose administration. However, only the 
prediction model for counts of administer HPV vaccine doses showed statistical 
significance with indicators of HD clinic access: public transit and the number of HD 
private clinics. The prediction model for HPV vaccination dose coverage rates included 
Tdap vaccinated adolescents and was a better fit for the data because of lower AIC and 
RMSE values. Therefore, among adolescents who have received the Tdap vaccine, the 
dose coverage rate prediction model identified two prognostic factors of rural residency 
and the racial category of White as statistically significantly associated in a negative 
direction with administered doses of the HPV vaccine at the county level. Further 
examination of these demographic variables may explain the additional differences 
between HPV and Tdap vaccine uptake because in the prediction model for counts of 
administered HPV doses, the negative effect of rural residency was less (0.03% compared 
81 
 
to a 0.72% effect in the dose coverage rate prediction model) and the White racial 
category did not show statistical significance.   
 In relation to public health efforts, the National Immunization Survey-Teen (NIS-
Teen) only provides state and national level rates with some large regional variation that 
can be examined. This study used prediction modeling and public health data sources, to 
estimate county level HPV vaccination rates. This novel approach enables people 
working at the community level to use these data to inform HPV vaccination promotion 
outreach efforts because this study showed that adolescents receiving the Tdap vaccine, 
the White racial category and rural residency affect the administration of HPV vaccine 
doses. These results are similar to previous studies that found decreased HPV vaccine 
initiation in rural communities18,19 and among non-Hispanic white adolesents20 and that 
the coadministration of the Tdap vaccine is helpful for HPV vaccine uptake21. These 
results were different from previous studies that found significant associations of county 
level estimates with Hispanic ethnicity, county poverty, household and percentage of 
uninsured22,23. However, these differences may be due to the limitation of the study 
population to girls.  
Limitations 
 There are several limitations to acknowledge in this study. Counts of administered 
vaccine doses are only from clinic sites that report to the state’s immunization registry. 
As such, there may be administered vaccination doses that are not accounted for and 
result in the underestimation of administered HPV and Tdap vaccine doses. Second, 
adolescents should have just received one dose of the Tdap vaccine within the study 
period, but it is possible that duplication vaccination may have occurred for a small 
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number of patients. Third, these prediction estimates are not geographically weighted to 
account for spatial variability. This absence may be evidenced by the rate prediction 
model’s coverage probability of 98%, which is a little high and may indicate some 
inaccuracy of those predictions due to the confidence interval being wider than 
necessary14 but this coverage probability also highlights valid and precise predictions. 
There are several strengths to this study. This study is one of the first to predict HPV 
vaccine dose coverage rates among adolescents who received the Tdap vaccine at the 
county level. These results found multiple statistically significant variables associated 
with HPV vaccine dose administration but emphasize rural residency and the White racial 
category as the variables to account for with HPV vaccination efforts. Additionally, this 
methodology can be used in different states that have vaccination registries with 
disaggregated population-level data to estimate small area HPV vaccination rates or these 
models can be generalized to other states with similar population demographics.  
Conclusion 
Overall, this study showed the effect of accounting for adolescents who have 
received the Tdap vaccine when investigating HPV vaccine dose administration.  The 
rate prediction model used in this study has important implications for HDs since state 
immunizations resources and immunization service delivery are organized as the county 
or local level. Using adolescents who have received the Tdap vaccine as a sample 
population established access to vaccines and controlled for multiple confounders such as 
vaccination ineligibility, vaccine exemption, adolescents with parents opposed to 
vaccination and no access to vaccination services. Therefore, within this population, 
increases in rural communities and the White racial population percentages were 
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identified as significant predictors of a decrease in HPV vaccine dose administration. 
Epidemiologists within HDs, program planners and health educators could use these data 
to focus HPV vaccination intervention efforts among non-Hispanic whites and in rural 
communities. To further improve HPV vaccination interventions, future work is needed 
with the use of geographically weighted regression models to improve predictions of 
HPV vaccination dose administration by accounting for spatial dependence in addition to 
overdispersion because this could incorporate the variability for other unmeasured 
factors. Additional small area studies on additional vaccines recommended by the 
Advisory Committee on Immunization Practices (ACIP) such as Meningococcal 
conjugate, Measles, mumps and Rubella (MMR) and hepatitis B (HepB) would help to 
evaluate the application of predictive and other modeling strategies estimating county 





Table 1. Overall Population Demographic Characteristics 
  Georgia 
Counties 159 
HPV vaccination coverage trend:  
≥ 1 dose, all adolescents aged 13-17*  
(United States overall)* 
  
2016 (60.4 %) 67.3% 
2017 (65.5 %) 64.3% 
2018 (68.1 %) 68.1% 
Tdap vaccination coverage trend:  
≥ 1 dose, all adolescents aged 13-17*  
(United States overall) 
  
2016 (88.0 %) 92.8% 
2017 (88.7 %) 93.3% 
2018 (88.9 %) 94.2% 
Race Ethnicity§   




American Indian/Alaskan Native 0.4% 
Native Hawaiian/Other Pacific Islander 0.1% 
Below 18 years of age§ 24.1% 
Education attainment §   
Highschool graduate or higher 87.5% 
Median Household Income§ $58,700 
Under 19 uninsured § 7.2% 
Under 19 insured § 92.8% 
Under 18 below poverty level§ 21.5% 
Living in rural area¶ 24.9% 
Living in urban area¶  75.0% 
 
Data Sources:  
* (Walker et al., 2019) 
§ (U.S. Census Bureau, 2015-2019 American Community Survey 5-Year 
Estimates) 


















Table 2. Results of count prediction model for administered doses of HPV vaccine 
 
Variables estimate Exp(estimate) P- value 
Intercept 5.61 273.66 1.35 e-06 
rural -3.44 0.03 < 2 e -16 
education 2.80 16.52 0.01 
poverty -2.25 0.10 6.70 e-06 
age 3.91 50.04 0.02 
Asian -12.30 0.00 0.0006 
Hispanic 3.20 24.49 0.001 
Public transit (yes) 0.28 1.32 0.02 
HD private clinics 0.04 1.04 2.60 e-11 
 
HPV = human papillomavirus; HD = health department 
Table 3. Results of coverage rate prediction model for administered doses of HPV 
vaccine among adolescents who received the Tdap vaccine 
Variables estimate Exp(estimate) P- value 
Intercept 0.65 1.92 1.83 e-08 
rural -0.33 0.72 0.001 
White -0.68 0.51 5.33 e-05 
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7.1 Abstract  
Objective: To use GA as a predictor model to provide greater insight of where to more 
efficiently allocate HPV vaccination resources at the county level within SC and inform 
the implementation and dissemination of HPV vaccination interventions that focus on the 
use and quality of state immunization resources. 
Methods: Using a cross sectional study design, secondary data were collected from 2015 
– 2019 estimates of the American Community Survey, the Georgia Department of Public 
Health, Georgia Registry of Immunization Transactions and Services (GRITS), and the 
Statewide Immunization Online Network of South Carolina Department of Health and 
Environmental Control (SC DHEC) for the years 2016 to 2018 for all counties of GA and 
SC. The study population was all male and female adolescents aged 12-18 in SC based on 
the age groups reported by DHEC’s SIMON and available census data. The number of 
adolescents who received one dose of the Tdap vaccine was used as an offset variable to 
calculate HPV vaccination coverage rates. Using the beta estimates of white and rural 
from the final GA prediction model, three predictive models for SC were developed using 
negative binomial regression to compare three different time spans for the best model fit.  
Results: The best fitting prediction model for SC was for the 2018 one-year time span 
even though the prediction model based on GA was developed using 2016-2017 data. 
This suggests that the HPV vaccination coverage prediction model is more helpful when 
looking at a single subsequent year. Negative residual estimates indicated over prediction 
and the counties of Charleston, Greenville and Richland had the largest differences 
between their observed and predicted HPV vaccination coverage rates. 
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Conclusion: These results suggests the need for implementation and dissemination of 
HPV vaccination interventions that focus on the use and quality of state immunization 
resources in Charleston, Greenville and Richland counties. The observed HPV 
administered dose coverage in these counties is not largely indicative of white and rural 
county residents and adolescents who have received the Tdap vaccine; otherwise the 
predicted administered dose coverage rates would be closer to the observed. These results 
highlight the need for prediction modeling studies at a local level to help with public 
health decision making, low HPV vaccination coverage and limited or no immunization 
registry data for small geographic areas. 
 
 
Keywords:  Prediction modeling, HPV vaccine, South Carolina, Georgia, immunization 




7.2 Introduction  
 National and regional efforts are being made to increase Human Papillomavirus 
(HPV) vaccination to 80% 1. The between state variation of HPV vaccination may be due 
to limited HPV vaccination surveillance2. Since HPV infections and most HPV-
associated conditions are not a nationally notifiable2 health-care claims data from 
adolescents and adults with employer-provided private health insurance in the United 
States are used to examine the population effectiveness of HPV vaccinations on HPV 
infections3. Furthermore, within state variability of HPV vaccination is not commonly 
studied. This may be due to the lack of state immunization registry data available at the 
zip code and county level4,5. These limited data on HPV prevalence in small geographic 
areas contribute to a limited capacity to characterize vaccination at smaller geographic 
levels such as county and zip code6. With immunization resources often delivered and 
utilized at the county level7, to assess HPV vaccine usage, a proxy measure for 
vaccination coverage is dose administration8.   
The states of Georgia (GA) and South Carolina (SC) are both in public health 
region IV and therefore share the same regional office for programs and policies through 
the U.S. Department of Health and Human Services (HHS) (Figure 2). Despite the 
difference in the number of counties, GA and SC share similar population demographic 
characteristics9–11 (Table 1). During the years of 2016 to 2018, the estimated HPV 
vaccination coverage trends of GA’s Tdap and HPV vaccination rates were consistently 
near or greater than the national average. Conversely, SC was consistently below the 
national average with the lowest HPV vaccination coverage estimate in the United States 
in 2016 according to the National Immunization Survey – Teen data12. Systematic 
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underuse of services that impact health by populations that share similar demographic 
characteristics may indicate a problem with equity of access13. Hence, access may be a 
significant driver of the different HPV vaccination rates between GA and SC. GA has 
comprehensive adolescent HPV vaccination data available through the Georgia 
Immunization Registry (GRITS) of the Georgia Department of Public Health at the zip 
code level that can be aggregated to the county level using Zip Code Tabulation Areas. 
SC does not have zip code level, but rather counts of administered HPV vaccine doses at 
the county level available through their Statewide Immunization Online Network. In 
order to explore these differences at the county level in SC, the availability of zip code 
level HPV vaccination data in GA, coupled with its similar population demographics to 
SC, supports GA as a suitable model state for developing a working plan to increase SC’s 
county level HPV vaccination coverage rates.   
Therefore, the objective of this research was to use GA as a predictor model to 
provide greater insight of where to more efficiently allocate HPV vaccination resources at 
the county level within SC and inform the implementation and dissemination of HPV 
vaccination interventions that focus on the use and quality of state immunization 
resources. The hypothesis is that differences in SC’s vaccination coverage between 
observed and predicted rates will be identified.  
7.3 Methods 
Data  
Using a cross sectional study design, secondary data were collected from 2015 – 
2019 estimates of the American Community Survey, the Georgia Department of Public 
Health, Georgia Registry of Immunization Transactions and Services (GRITS), and the 
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Statewide Immunization Online Network of South Carolina Department of Health and 
Environmental Control (SC DHEC) for the years 2016 to 2018 for all counties of GA and 
SC. The study population was all male and female adolescents aged 12-18 in SC based on 
the age groups reported by DHEC’s SIMON and available census data. For the predicted 
HPV vaccination coverage rate, adolescents who have received one dose of the Tdap 
vaccine were the sample population to establish access to vaccines and control for 
multiple confounders such as vaccination ineligibility, vaccine exemption, adolescents 
with parents opposed to vaccination and no access to vaccination services. To calculate 
the observed HPV vaccination coverage rate, the counts of administered HPV vaccine 
doses were reported by SC DHEC for ages 13-18 and the total number of adolescents in 
South Carolina were from ages 12-17 because it was the closest prespecified age group 
available in the US Census data for years 2016, 2017 and 2018. 
Statistical Modeling & Analyses  
The GA prediction model applied to SC data was developed using 1) adolescents 
aged 13-17. 2) Variables related to indicators of health care access via health care 
utilization13: the number of public health department clinics, the number of health 
department private clinics and the number of HD clinics with VFC provider registration. 
3) A variable related to health equity14: public transit transportation. 4) Predictor 
variables from factors associated with HPV vaccination based on a literature review6,15,16: 
age (percent under 18 years) , sex (percent of total population), race/ethnicity (percent of 
population), socioeconomic status (percent below poverty level under 18), education 
(high school graduate or higher percentage), median household income, health insurance 
(percent uninsured and insured under age of 19 years) and resident type (urban and rural 
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percentage). All variables were aggregated to county level using Zip Code Tabulation 
Areas (ZCTAs). The final GA prediction model with the best performance only included 
the predictor variables of white and rural.   
Using the beta estimates from the final GA prediction model, three predictive 
models for SC were developed using negative binomial regression. All the models also 
included the number of adolescents who received the Tdap vaccine as an offset (i.e., 
constant term) on the log scale to convert the HPV vaccine administered dose counts to 
HPV vaccination coverage rates. Model 1 predicted HPV vaccination coverage for years 
2016 and 2017 combined to estimate the same year time span of the data used to develop 
the GA prediction model. Model 2 predicted HPV vaccination coverage for year 2018 to 
estimate the year following the time span of the data used to develop the GA prediction 
model, and model 3 predicted HPV vaccination coverage for years 2016, 2017 and 2018 
combined to estimate the years included and after the time span of the data used to 
develop the GA prediction model. To evaluate prediction model performance, residuals 
were assessed and the Root Mean Square Error (RMSE) was calculated. The residual is 
the difference between observed and predicted administered HPV vaccine rates. The 
closer the residuals are to zero, the better the model fits the data. Residual outliers were 
calculated using the Interquartile Range (IQR). The comparative size of RMSE indicates 
model fit of how close the observed data points are to the model’s predicted values. 
Hence a smaller RMSE value indicates the better prediction model. Regression analyses 
and model predictions were implemented in R V.3.6.3 software packages17. Choropleth 
maps18 of observed and predicted administered HPV vaccine rates were created with SAS 
statistical software version 9.4 19.   
95 
 
 7.4 Results 
Data Maps 
 Choropleth maps show the observed administered HPV vaccine coverage 
compared to the predicted administered HPV vaccine coverage among Tdap vaccinated 
adolescents. For all three time periods, the clustering patterns of observed and predicted 
rates of HPV vaccine coverage across counties are somewhat similar. However, there is a 
clear pattern of increased predicted rates is some counties (Figure 1).  
HPV vaccine dose coverage 2016-2017 
 The negative residual estimates of the prediction model for HPV vaccination dose 
coverage 2016 – 2017 can be interpreted as the average coverage rate of administered 
HPV vaccine was over predicted by 721 doses based on the mean, 25% of coverage rates 
were over predicted by 896 doses based on the first quartile and 75% of coverage rates 
were over predicted by 191 doses based on the third quartile (Table 2). Figure 2 shows 
the values of the residuals for each county for 2016 - 2017. Negative residual values 
indicate over prediction. The lighter shades indicate a range of larger differences between 
observed and predicted HPV vaccination coverage and the darker shades indicate a 
smaller range of differences. Of the lighter shaded counties (i.e. counties with larger 
differences), Figure 3 shows that the residuals of three counties were calculated to be 
outliers (i.e. abnormally different): 10 – Charleston, 23- Greenville and 40 – Richland. 
Therefore, these counties need further examination to understand why the predicted HPV 
vaccination coverage was much higher than the observed compared to the other counties 





HPV vaccine dose coverage 2018 
 The negative residual estimates of the prediction model for HPV vaccination dose 
coverage 2018 can be interpreted as the average coverage rate of administered HPV 
vaccine was over predicted by 339 doses based on the mean, 25% of coverage rates were 
over predicted by 447 doses based on the first quartile and 75% of coverage rates were 
over predicted by 77 doses based on the third quartile (Table 2). Figure 2 shows the 
values of the residuals for each county for 2018. Of the lighter shaded counties (i.e. 
counties with larger differences), Figure 3 shows that the residuals of three counties were 
calculated to be outliers: 10 – Charleston, 23- Greenville and 40 – Richland. Therefore, 
these counties need further examination to understand why the predicted HPV 
vaccination coverage was much higher than the observed compared to the other counties 
for 2018. The RMSE for this model was 553.8.  
HPV vaccine dose coverage 2016-2018 
The negative residual estimates of the prediction model for HPV vaccination dose 
coverage 2016 - 2018 can be interpreted as the average coverage rate of administered 
HPV vaccine was over predicted by 1,060 doses based on the mean, 25% of coverage 
rates were over predicted by 1,362 doses based on the first quartile  and 75% of coverage 
rates were over predicted by 282 doses based on the third quartile (Table 2).  Figure 2 
shows the values of the residuals for each county from 2016 - 2018. Of the lighter shaded 
counties, Figure 3 shows that the residuals of three counties were calculated to be 
outliers: 10 – Charleston, 23- Greenville and 40 – Richland. As outliers, these counties 
need further examination to understand why the predicted HPV vaccination coverage was 
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much higher than the observed compared to the other counties for 2016 - 2018. The 
RMSE for this model was 1735.3.  
7.5 Discussion  
Interpretation 
In this study vaccination coverage rates of administered HPV vaccine doses 
among Tdap vaccinated adolescents in South Carolina were predicted using a model 
developed from GA. GA’s availability of zip code level HPV vaccination data coupled 
with its similar population demographics to SC, supports GA as a novel and suitable 
model state for developing a working plan to increase SC’s county level HPV vaccination 
coverage rates. These prediction models are also unique because the Tdap vaccine is a 
one-shot series and the HPV vaccine is a two-shot series before the age of 15 and a three-
shot series after the age of 15. These predictions highlight what HPV vaccination 
coverage rates could be if each adolescent that received a Tdap vaccine received at least 
one dose of the HPV vaccine.  Therefore, these predictions are best compared to HPV 
vaccination initiation instead of series completion.  
Three prediction models were designed to evaluate which time span best fit the 
data. The negative residuals values of the counties indicate over prediction. The 
differences of HPV vaccine coverage rates were illustrated with multiple choropleth 
maps and supported with quantitative analyses. Under the prediction model assumptions, 
results clearly show that the predicted HPV vaccine coverage rates among Tdap 
vaccinated adolescents were higher than observed rates among all SC adolescents. This 
over prediction is interesting because the prediction model accounts for the variables of 
white race and rural residency. Therefore, these results suggest that among South 
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Carolinians within the white racial category and rural counties, if the adolescents who 
received the Tdap vaccine also received the HPV vaccine, the number of HPV vaccine 
administered doses would be greater. Accordingly, this frame of reference is useful to 
public health professionals and clinicians because it supports the co-administration of the 
HPV vaccine with the Tdap vaccine.   
The best fitting prediction model for SC was for year 2018. This is interesting 
because the prediction model based on GA was developed using 2016-2017 data. This 
suggests that the HPV vaccination coverage prediction model is more helpful when 
looking at a subsequent year. Within this model all of the counties fell below the national 
average of 68.1% for 201820. However, the counties of Charleston, Greenville and 
Richland had the largest differences between their observed and predicted HPV 
vaccination coverage rates. These residual differences suggests the need for further 
investigation because 1) the prediction model was based on county level rural residency 
and the white racial category but all three of these counties are designated as urban by the 
U.S. Census Bureau, the U.S. Department of Agriculture, Economic Research Service 
and the U.S. Office of Management and Budget21. Therefore, these residuals suggest that 
the observed HPV administered dose coverage rates in these counties are not largely 
indicative of white and rural county residents, because the predicted administered dose 
coverage rates would be closer to the observed.  2) Predictions were made using a subset 
of the population, adolescents who received the Tdap vaccine. Therefore, these residuals 
also suggest that the observed HPV administered dose coverage rates in these counties 
are not largely indicative of white and rural county residents and adolescents who have 
received the Tdap vaccine. These results highlight that prediction modeling studies are 
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needed at a local level because many of the HPV vaccine modeling studies designed to 
help with public health decision making are at the national and state level. 
This study showed that predicting and visualizing HPV vaccination coverage rates 
at the county level is helpful for identifying within state variability and indicating 
counties that need further examination. There are no studies to our knowledge that use 
prediction modeling for HPV vaccination coverage rates or vaccine dose administration 
at the county level6,22. Many other studies use predictive modeling to assess HPV 
knowledge and behavior 15,23–26. However, the results of this study are similar to previous 
studies that found that visualizing vaccination data at the county level can help multiple 
stakeholders, such as local and state health departments, pharmacists, insurers, and 
nonprofit organizations determine where to focus financial and physical resources to 
improve HPV vaccination and identify gaps in vaccine delivery 27–29.  
Limitations 
There are several limitations to acknowledge in this study. First, currently it is not 
possible to differentiate if an administered dose was given to initiate or complete an HPV 
vaccination series due to immunization registry data not being linked with vital records. 
With the data not being able to distinguish between the doses, it better to use HPV 
initiation a comparator for the predicted HPV vaccine administered dose coverage rates 
in this study since adolescents who received one dose of the Tdap vaccine were used to 
create the predictions. Second, the assumption that previously collected data can predict 
the future is not always accurate. Using associations from historical data to predict the 
future also assumes there are certain lasting conditions, such as number of doses needed 
to complete the vaccine series and age range of use. These inaccurate assumptions of 
lasting conditions can lead to inaccurate estimates30. Another potential complication with 
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predictive modeling is the possibility of new variables that have not been considered or 
even defined are critical to the outcome such as the number of school based health 
centers/clinics within a county, which could serve as an additional source of HPV vaccine 
delivery especially in rural counties. Until these and other measures become available, 
the use of proxy measures will need to be taken with caution. However, there are also 
several strengths to this study. This study is one of the first studies to apply predictive 
modeling to HPV vaccination dose administration at the county level. Furthermore, this 
study innovatively used a vaccinated population for modeling estimates, which supports 
the importance of co-administering the HPV vaccine with other scheduled adolescent 
vaccines to improve HPV vaccination rates. Another strength is that this methodology is 
applicable to other states with similar population demographics, low HPV vaccination 
coverage and limited or no immunization registry data for small geographic areas. 
Conclusion  
 Overall, this study showed that immunization registries can be informative data 
sources for public health practitioners to identify priorities for HPV vaccinations 
interventions in targeted locations. Based on these results, a working plan to address the 
current limitations of SC’s HPV vaccination coverage at the county level is to 
disaggregate statewide immunization resources and identify barriers to HPV vaccine 
access and delivery in Charleston county in the Lowcounty, Greenville county in the 
Upstate and Richland county in the Midlands region.  Public health practitioners should 
first examine the similarities of county level characteristics such as race/ethnicity 
percentages, areas of rural residency and provider shortage areas because prior research 
has shown them to be associated with variation in HPV vaccination6. Once these county 
level area characteristics are identified, then practitioners can focus on regional 
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differences to develop systems level interventions that include HPV vaccine delivery and 
access to HPV vaccination services. To better inform HPV vaccine delivery, future work 
is needed with the use of health indices such as the social vulnerability index to help 
public health officials and practitioners plan, prepare and respond to public health needs. 
Additional predictive studies using other adolescent vaccines such as the meningococcal 
conjugate vaccine (MCV4) or other proxy measures for vaccination usage such as 
provider orders, would help to evaluate the application of predictive modeling strategies 








Figure 1. Maps of observed and predicted HPV vaccine coverage rates 
 
     
 
     
 
    
103 
 



















































Table 1. Population Demographic Characteristics  
  Georgia South Carolina 
Counties 159 46 
HPV vaccination coverage trend:  
≥ 1 dose, all adolescents aged 13-17*  
(United States overall)* 
 
  
2016 (60.4 %) 67.30% 44.20% 
2017 (65.5 %) 64.30% 59.60% 
2018 (68.1 %) 68.10% 63.70% 
Tdap vaccination coverage trend:  
≥ 1 dose, all adolescents aged 13-17*  
(United States overall) 
 
  
2016 (88.0 %) 92.80% 77.50% 
2017 (88.7 %) 93.30% 89.40% 




Black/African American 31.30% 26.80% 
White 52.80% 63.80% 
Asian 4.20% 1.70% 
Hispanic 9.60% 5.70% 
American Indian/Alaskan Native 0.50% 0.50% 
Native Hawaiian/Other Pacific Islander 0.10% 0.10% 




Highschool graduation 81% 84% 




Median Household Income+ $56,100  $50,700  
Uninsured children+ 7% 4% 
Children in poverty+ 22% 22% 
Living in rural area+ 24.90% 33.70% 
 
Data Sources:  
* (Walker et al., 2019) 






Table 2. Results for the estimates of South Carolina Prediction Models 
 Residuals  
South Carolina 
Prediction Models 
Mean 1st Quartile 3rd Quartile RMSE 
Model 1: HPV Vaccination 
coverage for 2016 - 2017 
-721.1 -896.0 -190.9 1183.6 
Model 2: HPV Vaccination 
coverage for 2018 
-338.6 -447.1 -76.8 553.8 
Model 3: HPV Vaccination 
coverage for 2016 - 2018 
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8.0 DISCUSSION  
 HPV vaccinations are safe, effective, and long lasting1. However, they are being 
underutilized in the United States. A metric to assess vaccine usage is vaccination 
coverage, which can be measured using administered doses2. Factors associated with 
HPV vaccination coverage have been shown to include the uptake of other adolescent 
vaccines, gender, race/ethnicity, socioeconomic status, religiosity, political ideology, 
education policies and insurance status. As a result, national and state efforts are being 
made to increase HPV vaccination coverage to 80% by the year 20303. However, health 
care utilization can also be determined by access to public health resources that are often 
managed by state the Health Department (HD): such as childhood and adolescent 
vaccinations administered by school nurses and at public or private health clinics, 
community education and outreach, vaccine program enrollment, and immunization 
registry reporting4–6. To effectively monitor public health resource utilization, data 
beyond the state level is needed but this is a limitation for some states. Therefore, the 
underutilization of the HPV vaccine may be due to limited surveillance. Thus, the main 
goal of this research was to generate a predictive model of county level HPV vaccination 
coverage rates in GA and SC to address access barriers to HPV vaccine uptake. The main 
hypothesis was that HPV vaccine coverage rates are associated with the equity of access 
to HD clinics.  
Using a secondary data analysis of vaccination data from both states, this research 
was conducted in three specific Aims. The first Aim characterized all counties in GA by 
quantifying administered doses of the HPV and Tdap vaccines collected by the state 
health department immunization registries and indicators of HD clinic access. Indicators 
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of HD clinic access consisted of number of private and public HD clinics, number of HD 
clinics registered in the VFC program and the availability of public transportation. This 
Aim incorporated choropleth maps, regression modeling and Bayesian spatial analysis. 
The results of Aim 1 showed that administered doses of the Tdap vaccine and the HPV 
vaccine exhibited spatial patterns shown with maps and a spatial relationship across 
counties. Accounting for this spatial dependence, the number of private health 
department clinics had a significant positive effect on the administered Tdap vaccine 
doses and the availability of public transportation had a significant positive effect on 
administered HPV vaccine doses. 
Building from the first Aim, the second Aim predicted the association between 
HPV vaccination coverage and HD clinic access in GA at the county level among Tdap 
vaccinated adolescents. This Aim incorporated known factors associated with HPV 
vaccination coverage in addition to hypothesized indicators of HD clinic access, and 
adolescents who received the Tdap vaccine as a sample population to establish access to 
vaccines and control for multiple confounders. The results of Aim 2 showed that the best 
prediction model for HPV vaccination coverage was not associated with indicators HD 
clinic access but had a statistically significant negative association with the White racial 
category and rural residency. Therefore, within this population, the White racial category 
and rural counties were identified as predictors of decreasing HPV vaccine dose 
administration. 
Extending from the second Aim, the third Aim used GA as a predictor model to 
provide greater insight of where to more efficiently allocate HPV vaccination resources at 
the county level within SC and inform the implementation and dissemination of HPV 
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vaccination interventions that focus on the use and quality of state immunization 
resources. This Aim incorporated the betas from the best prediction model using GA’s 
comprehensive HPV vaccination data and applied them to SC county data over three 
different time spans. The results of Aim 3 showed that the best fitting prediction model 
for SC was for the 2018 one-year time span. Negative residual estimates indicated over 
prediction and the counties of Charleston, Greenville and Richland had the largest 
differences between their observed and predicted HPV vaccination dose coverage. 
Therefore, the residuals of these three counties suggest the need for further investigation 
of what HPV vaccination resources are available, being used and needed. 
 Based on all three Aims, HPV vaccination coverage rates are not associated with 
this study’s unique variables of HD clinic access as hypothesized. However, the 
indicators of HD clinic access did show statistical significance with counts of HPV 
vaccine administered doses; as well spatial dependence with the counts of HPV vaccine 
administered doses. This research showed HPV vaccination variability at the county level 
and presented reproducible methodologies that can be used by public health researchers 
and practitioners in states with low HPV vaccination coverage and limited or no 
immunization registry data for small geographic areas.    
While research on HPV vaccination has been conducted for over 10 years, 
incorporating geographic factors and analyses is not commonly used7–9. Therefore, this 
research contributed to the current literature and showed the importance of considering 
spatial variation at the county level when examining HPV vaccine dose administration. 
Other state based studies also found that HPV vaccination rates vary geographically10, 
HPV vaccination has a strong spatial dependence when identifying and estimating factors 
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associated with HPV vaccine uptake11 and that spatial accessibility to vaccination 
providers increases overall vaccination12. Using aggregated zip code level data, this 
research showed that adolescents receiving the Tdap vaccine, the White racial category 
and rural residency affect the administration of HPV vaccine doses. Other zip code based 
studies found decreased HPV vaccine initiation in rural communities13,14 and among non-
Hispanic white adolesents15 and that the coadministration of the Tdap vaccine is helpful 
for increasing HPV vaccine uptake16. Using predictive modeling, this research showed 
that predicting state immunization data at the county level was helpful for identifying 
within state variability and indicating counties that need further examination. This 
methodology was uniquely applied to HPV vaccination coverage because other 





9.0 CONCLUSION   
Local immunization coverage rates vary widely and the extent to which public 
health services are delivered depends on the level of surveillance performed by the 
Health Department. This research uniquely utilized the tools of mapping and prediction 
modeling to extend HPV vaccination coverage rates to the county level. Mapping spatial 
patterns provided a visual context to HPV vaccination data that is helpful for informing 
the development of public health interventions and guiding the provision of health 
services financially and physically. The underuse of the HPV vaccine is a serious but 
correctable threat to progress against cancer. Using the models or methodology from this 
research could inform specific recommendations for new strategies and the adaptation of 
current efforts to increase HPV vaccination coverage in SC and other states with low 
HPV vaccination rates. Furthermore, this research could then be used to predict 
correlations to the incidence of HPV-associated cancers. This would aid the field of 
health services research to understand and address health care inequities among 
populations with high rates of HPV cancers, which may help reduce public health costs, 






10. FUTURE DIRECTIONS  
To enhance the use of predictive modeling with HPV vaccination at the county 
level, new variables need to be considered and defined because they could be critical for 
improving estimations and reducing confounding. For example, the number of school-
based health centers/clinics within a county could serve as an additional source of HPV 
vaccine delivery especially in rural counties. The reproducibility of prediction models 
also allows them to be used by various levels of public health practitioners to inform and 
guide their planning, dissemination and implementation of interventions. Additionally, 
health services research would benefit from the disaggregation of statewide resources and 
data from immunization registries at the county level or smaller. With more small area 
data, subtle barriers to HPV vaccine uptake not seen at the state or national level could be 
identified. Furthermore, with the availability of more small area data, the importance of 
using maps to visualize the data highlights the need for the collaboration of multiple 
stakeholders, such as local and state health departments, pharmacists, insurers, 
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